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The present study investigated the effects of an opioid antagonist, naloxone (NAL),
on plasma concentrations of catecholamines (norepinephrineandepinephrine),
glycerol, and free fatty acids (FFA) and fatty acid and carbohydrate oxidation (indirect
calorimetry) during exercise at an intensity above or below lactate threshold (LT) in 20
trained males (age, 24.1 ± 4.4 yr; VO2peak, 62.7 ± 6.0 mlkg-1min-1). The subjectswere
randomly assigned to one of two groups performing 30-minute cycling atan intensity
either 10% above or below their individual LT. Each subject in eachgroup performed
two exercise tests in separate occasions with an injection of either NAL (1.2 mg) or
saline placebo (PLC) in a double-blind, counterbalanced order. NAL or PLC was
injected through a Teflon catheter located ina radial vein 15 minutes before exercise.
Plasma levels of norepinephrine increased during exercise above and below LT andwere
significantly higher above LT than below LT (p < 0.05). NAL administration did not
significantly alter plasma levels of catecholamines during exercise either above or below
LT. Plasma levels of glycerol and FFA during exercise did not differ between the two
intensities. NAL failed to produce significant changes in plasma glycerol or FFA either
above or below LT. Fatty acid oxidation during exercise was identical between the two
intensities, whereas carbohydrate oxidation was significantly higher above LT than
below LT (p < 0.05). NAL did not significantly influence fatty acid and carbohydrate
Redacted for privacyoxidation during exercise either above or below LT. In conclusion, during exercise atan
intensity 10% above or 10% below LT, endogenous opioidmay not play regulatory
roles in catecholamine secretion and substrate metabolism. Enhanced carbohydrate
oxidation contributed to elevated energy demands during exercise above LT.®Copyright by Hirotaka Hikoi
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CHAPTER 1
Introduction
A number of studies have documented endogenous energy substrate metabolism
during exercise. It has long been recognized that endogenous fat is an important fuel
source during exercise, but the regulatory mechanisms of fatmobilization and
utilization have not been entirely elucidated. The hormonal regulation of fat metabolism
has been investigated in relation to intensities during prolonged exercise. Plasma
concentrations of lipolytic hormones such as catecholamines increase with increasing
intensities during exercise. Also, endogenous opioid peptides such as f- endorphin (B-
EP) possibly play a role in the regulation of catecholamine secretion and, in turn, fat
metabolism during exercise. However, the relation between the involvement of
catecholamines and endogenous opioids in regulation of fat metabolism at different
exercise intensities is still unclear.
General Concept of Substrate Utilization in Relation to Exercise Intensity
In general, a relative shift in utilization of endogenous energy substrates from fat to
carbohydrates (CHO) to meet energy requirements in response to acute prolonged
exercise is largely associated with exercise intensities in humans, as well as exercise
duration and status of adaptation to training (Brooks, & Mercier, 1994; Kanaley,
Mottram, Scanlon, & Jensen, 1995; Romijn et al., 1993). According to the "crossover"2
concept by Brooks and Mercier (1994), the relative energy contribution of CHO and
fat utilization changes along the continuum of exercise intensities. Belowa certain
exercise intensity (i.e., "crossover" point), fat oxidation predominates, and above that
intensity CHO utilization predominates toan increasing extent as exercise intensities
increase.
Increases in exercise intensities result in contraction-induced muscle glycogenolysis,
increased recruitment of fast glycolytic muscle fiber types, and enhanced sympathetic
nervous activity. A progressive reduction in oxidation of plasma free fatty acids (FFA)
with increased exercise intensities is counterbalanced by increased utilization of CHO
(blood glucose and muscle and liver glycogen) in order to maintain the totalenergy
production required at a given intensity (Romijn et al., 1993). An isotope tracer study
by Romijn et al. (1993) has shown that lipolysis in adipose tissuewas enhanced
maximally at 25% of maximal oxygen consumption (VO2max). In contrast, FFA
mobilization into plasma (the rate of appearance of plasma FFA) and oxidationwere
reduced as the exercise intensity increases to 65% and 85% VO2max. It has been of
interest that the exercise intensity at which CHO becomes predominantover fat as an
energy source during exercise correlates with the lactate threshold (LT) (Brooks, &
Mercier, 1994). Kanaley et al. (1995) observed that exercise intensities above LT
resulted in a significant reduction in the rate of FFAappearance (mobilization) as
compared with that below LT during prolonged running. There is evidence thatan
increase in arterial plasma lactate levels observed during heavy exercise results in
suppression of exercise-induced increases in plasma FFA and glycerol, suggestinga
direct anti-lipolytic effect of plasma lactate (Boyd, Giamber, Mager, & Lebovitz,
1974).
Fatty acid oxidationispossiblyassociated withplasma FFA availability
(mobilization) from adipose tissue during exercise (Hagenfeldt, Wahren, Pernow, &
Raf, 1972; Hodgetts, Coppack, Frayn, & Hockaday, 1991; Martin, 1996; Romijn,
Coyle, Sidossis, Zhang, & Wolfe, 1995). Hagenfeldt et al. (1972) observed that FFA3
uptake in muscle and liver was reduced when arterial FFA concentration was decreased
by an administration of nicotinic acid in resting humans. On the other hand, increased
arterial FFA caused enhanced muscle FFA uptake during rhythmic hand contractions
(Hagenfeldt, & Wahren, 1971). Plasma FFA oxidation appears to be identical to whole
body fatty acid oxidation during low-intensity exercise (Romijn et al., 1993). However,
during high-intensity exercise, the association between fatty acid oxidation and plasma
FFA availability differs from that during low-intensity exercise (Romijn et al., 1993,
1995).
Hagenfeldt and Wahren (1971) have reported that plasma FFA was completely
oxidized during low-intensity exercise but only about 60% oxidized at a higher
intensity.Also,increased plasma FFA availability bylipidinfusiondid not
significantly alter the respiratory exchange ratio during exercise at 70% of maximal
power output (van Baak, Mooij, & Wijnen, 1993). Whole body fatty acid oxidation
cannot be accounted for solely by plasma FFA oxidation during moderate- to hard-
intensity exercise (Kanaley et al., 1995; Romijn et al., 1993; Saltin, & Astrand, 1993).
An isotope tracer technique has revealed that lipolysis of intramuscular triglycerides
was stimulated maximally at 65% V02., resulting in enhanced oxidation of muscle
triglycerides (Romijn et al., 1993). The higher rate of fatty acid oxidation observed
during exercise at 65% as compared to that at 25% V02. wasaccomplished by the
increased rate of intramuscular triglyceride oxidation, while the rate of plasma FFA
oxidation was decreased due to reduced plasma FFA availability (Romijn et al., 1993).
Also, fatty acid oxidation during above-LT intensity exercise (79- 86% VO2max) did
not significantly differ from that during below-LT intensity exercise (70 - 72% VO2max)
(Kanaley et al., 1995). Conversely, plasma FFA availability was significantly reduced,
thus suggesting enhanced utilization of intramuscular triglycerides.
It has been reported that moderate- to high-intensity exercise enhanced intracellular
lipoprotein lipase activity of rat skeletal muscles, resulting in a significant reduction in
intramuscular triglyceride content (Oscai, Caruso, & Wergeles, 1982). Thus,itis4
suggested that mechanisms of regulation of lipolysis in adipose tissue would differ
from that of lipolysis of intramuscular triglycerides, which is not facilitated during low-
intensity exercise (Romijn et al., 1993). Indeed, relatively higher levels of plasma
glycerol were observed during high-intensity exercise than during low-intensity
exercise, indicating greater lipolysis of intramuscular triglycerides during high-intensity
exercise (Kanaley et al., 1995; Romijn et al., 1993).
However, at 85% V02,nax, the rates of intramuscular triglyceride and plasma FFA
oxidation eventually declined, thus resulting in reduced overall fatty acid oxidation
(Romijn et al., 1993). In fact, several studies have reported that during such intense
exercise, an elevation in plasma FFA due to a fat feeding or lipid infusion failed to
enhance FFA uptake and fatty acid oxidation (Hargreaves, Kiens, & Richter, 1991;
Vukovich et al.,1993). Romijn et al. (1995) also have documented that although
increased plasma FFA by lipid-heparin infusion resulted in a slight increase in fatty
acid oxidation during 30-minute cycling at 85% V02., the magnitude of increase was
minimal as compared with that at 65% VO2max. They have concluded that during
exercise at a high intensity, reduced fatty acid oxidation is not due solely to reduced
plasma FFA availability and that the regulatory mechanism of fat oxidation is likely to
differ between low- and high-intensity exercise.
Possible mechanisms blunting fat oxidation during high-intensity exercise have been
addressed: a) reduced plasma FFA availability, b) limited FFA transport into the
mitochondria due to inhibition of carnitine palmytol transferase I as a consequence of
elevated malonyl-CoA production via enhanced glycogenolysis and glucose uptake
(Romijn et al., 1993; Saha et al., 1997), c) reduced oxidative capacity in muscle due to
limited oxygen availability (Romijn et al.,1995), and d) depressed blood flow to
adipose tissue due to a-adrenergic inhibition (Romijn et al., 1993; van Book et al.,
1993). Also, more recruitment of fast-twitch muscle fibers which have a low capacity
of fatty acid oxidation could be involved (Jeukendrup, Saris, & Wagenmakers, 1998b;
Peters, Dyck, Bonen, & Spriet, 1998). In oxidative muscle (rat soleus muscle) in which5
more hormone-sensitive lipase and 3-adrenoceptors are possessed, physiological
concentrations of epinephrine caused an increase in lip olysis but did not in glycolytic
muscle (epitrochlearis muscle) (Peters et al., 1998). In addition, reduced plasma FFA
availability might be due to a-adrenergic inhibition of lipolysis in adipose tissue during
high-intensity exercise. However, it has been suggested that the inhibition of lip olysis
may not likely occur, since, in fact, plasma levels of glycerol and the rate of glycerol
appearance were maintained even during high-intensity exercise (Kanaley et al., 1995;
Romijn etal.,1993). Thus, the underlying mechanisms of reduced plasma FFA
availability and fatty acid oxidation with increasing exercise intensities are still unclear.
Catecholaminergic Regulation of Lipolysis and Fatty Acid Mobilization and
Oxidation During Exercise
Lipolysis of triglycerides in the adipose tissue and muscle and fattyacid
mobilization into the circulation are mediated by neural and hormonal regulation.
Sympathetic nerve activity and the actions of hormones such as catecholamines
(norepinephrine, NE, and epinephrine, Epi), insulin, glucagon, adrenocorticotropin,
cortisol, growth hormone, and thyroid hormone are shown to be involved in the
regulation of lipolysis to varying degrees (Guyton, 1991). In humans, the most potent
lipolytic and anti-lipolytic hormones producing rapid and prominent effects are
catecholamines and insulin, respectively (Martin, 1996). An intravenous epinephrine
infusion enhanced serum FFA and blood glycerol levels at rest in trained (Martin et al.,
1984) and nondiabetic humans (Divertie, Jensen, Cryer, & Miles, 1997). On the other
hand, hyperinsulinemia inhibits lipolysis (plasma glycerol and FFA mobilization) and
fat oxidation (Bonadonna, Groop, Zych,Shank, & DeFronzo, 1990; Campbell,
Carlson, Hill, & Nurjhan, 1992).Hormone-sensitive triglyceride lipase in adipose tissue becomes activated b y
increased levels of catecholamines mediated via 3- adrenoceptors (Samra et al., 1996)
and by decreased levels of insulin in resting conditions (Wasserman, Lacy, Goldstein,
Williams, & Cherrington, 1989) and during exercise (Jensen, Cryer, Johnson, &
Murray, 1996). During exercise, plasma concentrations of insulin are decreased mainly
due to inhibitory effects of catecholamines (Jeukendrup, Saris, & Wagenmakers,
1998a). Subsequently, activated hormone-sensitive lipase rapidly causes hydrolysis of
the stored triglycerides (i.e., lipolysis), and then fatty acids and glycerol are released
into the circulation. During prolonged, exercise, Romijn et al. (1993) have observed that
plasma levels of catecholamines increased dramatically with increasing exercise
intensities (25 to 85% V02,,x). It has been reported that the lipolytic response to
catecholamine is enhanced by an acute bout of exercise (Savard et al., 1987).
However, an isotope tracer approach demonstrated that the rate of lipolysis in
adipose tissue did not elevate, and, in turn, the rate of FFA appearance in plasma
declined progressively with increasing exercise intensities (25% to 85% VO2n.,), thus
resulting in suppressed plasma FFA levels (Romijn. et al., 1993). It is suggested that
decreased FFA mobilization in plasma would be due not only to alterations in adipose
tissue lipolysis but also to limited transport capacity of FFA, resulting from increased
reesterification and/or entrapment of FFA within adipose tissue after lipolysis
(Hodgetts et al., 1991; Wolfe, Klein, Camaro, & Weber, 1990). However, it is still
unclear whether the paradoxical responses of FFA mobilization to higher-intensity
exercise, during which increased levels of plasma catecholamines are observed, are
attributed to either of these possible mechanisms.
Brooks and Mercier (1994) have mentioned that the effect of small rises in plasma
catecholamines dominates in favor of lipolysis and fat oxidation during low- to
moderate-intensity exercise, whereas further enhanced levels of plasma catecholamines
during high-intensity exercise facilitate muscle glycogenolysis. Muscle glycogenolysis
causes lactic acid production, and lactic acidosis subsequently inhibits lipolysis (Boydet al., 1974). Hierarchical effects of catecholamines with lipolytic and glycolytic roles
in sequence with increasing exercise intensities have also been addressed (Brooks, &
Mercier, 1994). Galster, Clutter, Cryer, Collins, and Bier (1981) have reported that
plasma levels of Epi which caused lipolysis of in vivo human adipose tissuewas far
less than those observed during exercise at77% VO2max
Catecholamines are known to have dual effects on lipolysis, stimulating via 0-
adrenoceptors and inhibiting via a2-adrenoceptors in human adipocytes (Hjemdahl, &
Linde, 1985; Wahrenberg, Engfeldt, Bolinder, & Arner, 1987; Wahrenberg, Lonnqvist,
& Arner, 1989). Wahrenberg et al. (1989) have found thata nonselective (3- and a-
adrenergic agonist (noradrenaline) with an a2-adrenergic antagonist (yohimbine)
stimulated lipolysis in isolated human adipose tissue in vitro toa greater extent as
compared with noradrenaline alone. Also, they have observed thata nonselective 13-
adrenergic agonist (isoprenaline) and a selective a2-adrenergic agonist (clonidine)
induced lipolytic and anti-lipolytic effects, respectively. It is well established that
lipolysis in human adipose tissue is mediated by both subtypes of pi- and 132-
adrenoceptors with cyclic AMP-dependent mechanisms, while the anti-lipolytic effect
is mediated by a2-adrenoceptors (Hjemdahl, & Linde,1985).Also,circulating
catecholamines (i.e., NE and Epi) stimulate in vivo lipolysis in humans.
Human adipose tissue lipolysishas been observed to be more sensitive to
stimulation by circulating Epi than NE (Galster et al., 1981; Hjemdahl, & Linde, 1983).
It has been mentioned that the lipolytic effect of Epi is assumed to be mainly mediated
by 132-adrenoceptors, whereas the lipolytic effect of NE secreted from sympathetic
nerve endings surrounding adipocytes is (31-mediated (Abumrad, Park, & Whitesell,
1986; Hjemdahl, & Linde, 1985). It has therefore been suggested that 01-mediated
(neurogenic) mechanisms are employed under basal conditions or mild stress, whereas
132-mediated (humoral) mechanisms (i.e., circulating Epi) are involved under severe
stress such as heavy exercise.8
Indeed, administration of a nonselective r3-adrenergic antagonist (propranolol)
inhibited exercise (50% V02 ,ax) -induced increase in lipolysis in humans, whereasa 131-
adrenergic antagonist (metoprolol) reduced the increase in lipolysis toa lesser extent
(Lundborg et al., 1981). On the other hand, an a2-mediated anti-lipolytic response to
circulating Epi has been observed in human adipose tissue. It should be noted that the
lipolytic effect of NE would be due partly to adrenergic inhibition of insulin secretion
possibly via an a-adrenergic effect (Hjemdahl, & Linde, 1985; Hodgetts et al., 1991;
Wasserman et al., 1989). Notably, the anti-lipolytic effect of Epioccurs with higher
concentrations than those required for lipolytic response in humans (Hjemdahl, &
Linde, 1985). Such high concentrations of circulating catecholaminesare usually
attained during exercise (Romijn et al., 1993).
In a study by Wahrenberg et al. (1987), effects of adrenergic agonist and antagonist
on in vitro lipolysis in isolated human adipose tissue were investigated after moderate-
intensity exercise (67% VO2max). They have documented thatan acute bout of exercise
further enhanced an increase in lipolysis observed at rest inresponse to nonselective (3-
and a-adrenergic agonist (noradrenaline) alone and in a combination with a selective a2-
antagonist (yohimbine),and a nonselectiven-agonist (isoprenaline).Also,the
magnitude of alteration was greater in response to noradrenaline ina combination with
yohimbine and to isoprenaline as compared with noradrenaline alone after exercise.
This result suggests the involvement of both 13- and a-adrenergic effects on adipose
tissue lipolysis during exercise and a blunted lipolytic response to noradrenaline due to
the a2-adrenergic effect.
However, it has been observed that the anti-lipolytic effect of a selective a2-
adrenergic agonist (clonidine) was not altered after exercise as compared with that
observed at rest (Wahrenberg et al., 1987). This suggests that (3-adrenergic effect would
be of more importance for adipose tissue lipolysis during exercise. Wahrenberg et al.
(1987) have thus concluded that although an increase in adipose tissue lipolysis may be9
due to either an increase in f3- adrenergic ora decrease in a2-adrenergic effect, the similar
effect of a2-agonist clonidine on lipolysis observed in resting and after exercise
indicates an unchanged a2-adrenergic effect inresponse to an acute bout of exercise.
More recently, an in situ technique for lipolysis using microdialysis in adipose
tissue has shown that different adrenergic mechanisms mediate lip olysis in human
adipose tissue at rest and during exercise (Amer, Kriegholm, Engfeldt, & Bolinder,
1990). Amer et al. (1990) have observed thata nonselective a-adrenergic antagonist
(phentolamine) enhanced glycerol levels in adipose tissue during resting, whereasa
nonselective 13-adrenergic antagonist (propranolol) did not change adipose tissue
glycerol levels. On the other hand, during moderate-intensity exercise (67% VO2max),
they found that phentolamine did not alter an exercise-induced increase in adipose
tissue glycerol levels, whereas propranolol reduced the increased glycerol levels. It has
therefore been concluded that a-adrenergic inhibition mainly modulates adipose tissue
lipolysis at rest, whereas 13-adrenoceptors predominantly stimulate lipolysis during
moderate-intensity exercise.
Also, van Baak et al. (1993) have reported that propranolol administration reduced
plasma levels of FFA and glycerol during prolonged cycling exercise at 70% of maximal
power output, suggesting 13-adrenergic regulation in adipose tissue lipolysis during
exercise. Moreover, it has been shown that nonselective (3- and (31-antagonists (nadolol
and atenolol, respectively) inhibited adipose tissue lipolysis toa similar extent during
exhaustive exercise in humans (Cleroux, Van Nguyen, Taylor, & Leenen, 1989).
Thus, the p-adrenergic stimulatory mechanism is likely to be of importance foran
increase in adipose tissue lipolysis during exercise, while the a-adrenergic inhibitory
mechanism may be involved in lipolysis to a lesser extent. The findings that adipose
tissue lip olysis was enhanced maximally during low-intensity exercise but not increased
at high intensities, despite large increases in plasma catecholamines (Romijn et al.,
1993), suggest that adipose tissue lipolysis would be sensitive to small increases in10
plasma catecholamines via p-adrenergic stimulation (Galster et al., 1981; Hjemdahl, &
Linde, 1983; Romijn et al., 1993). Also, since circulating Epi would bea more potent
hormone in human adipose tissue lipolysis than NE, lipolysis is suggested to bemore
sensitive to 132-adrenergic modulation (Hjemdahl, & Linde, 1983).
Moreover, inhibition of adipose tissuelipolysis by nonselectivef1- and PI-
antagonists during exercise implies that adipose tissue lipolysisis regulated by pi-
adrenoceptors, whereas intramuscular lipolysis would be mediated by p2-receptors
(Cleroux et al., 1989). Most recently, a microdialysis study has indicated that 132-
adrenergic modulation is of important for regulation of lipolysis in skeletal muscle in
humans, where as p,- and 133-adrenoceptors are involved in lipolysis in adipose tissue
(Hagstrom-Toft, Enoksson, Moberg, Bolinder, & Arner, 1998).
Thus, adipose tissue lipolysis is likely to be associated with the circulating levels of
catecholamines and lipolytic response to catecholamines (Wahrenberg et al., 1987). The
lipolytic and anti-lipolytic cascade of catecholamine effects appears to depend upon
the number of13- and a-adrenoceptors, the ratio of3-to a-receptors, and the affinity
of adrenoceptors to catecholamines in adipose tissue (Despres et al., 1984; Wahrenberg
et al., 1989). However, it has been demonstrated that P-adrenoceptor density, (3- and
a2-adrenoceptor binding capacity to the ligands, and ratio ofJ3-to a2-receptors were
not altered after exercise (Wahrenberg et al., 1987).
On the basis of all that is mentioned above, reduced mobilization and oxidation of
plasma FFA observed during intense exercise might be due to other mechanisms than
inhibited adipose tissue lipolysis per se via enhanced a-adrenergic regulation. It is
evident that adipose tissue lipolysis would be enhanced via 3- adrenergic mechanism
even during moderate- to high-intensity exercise (Amer et al., 1990; van Book et al.,
1993; Wahrenberg et al., 1987).
It has been reported that circulating NE and Epi caused vasoconstriction by a-
adrenergic stimulation and vasodilation by 32-adrenergic stimulation, respectively, in11
human adipose tissue (Hjemdahl, & Linde, 1983). However, both catecholamines
stimulated adipose tissue lipolysis via Pi and I32-adrenoceptors. Therefore, the finding
by Arner et al. (1990) that a nonselective a-adrenergic antagonist (phentolamine)
enhanced lipolysis in in vivo human adipose tissue at rest might be due partly to
reduced vasoconstrictioninadiposetissue,resultinginincreasedinflowof
catecholamines into adipose tissue (Hjemdahl, & Linde, 1985) and/or enhanced outflow
of FFA from adipose tissue into the plasma. Romijn et al. (1993) have shown that
plasma FFA availability was reduced during high-intensity exercise, despite an increase
in rate of glycerol appearance in plasma, indicating that lipolysis itself was actually
stimulated even at high intensities of exercise.
Glycerol derived from, lipolysis in adipose tissue and muscle is easily released into
the plasma because of its small size and water solubility (Hodgetts et al., 1991; Wolfe
et al., 1990), whereas FFA are hydrophobic and require a protein carrier of albumin to
be transported into the plasma (Romijn et al., 1993). Thus, it is suggested that a decline
in blood flow in the adipose tissue due to a-adrenergic inhibition results in reduced
FFA mobilization from adipose tissue during exercise, rather than reduced delivery of
catecholamines into the adipose tissue. The inhibition of adipose tissue blood flow may
cause accumulation of FFA within the tissue. It has been implied that cutaneous blood
flow,possiblyincludingadiposetissue,estimatedbyvenousocclusion
plethysmography and laser-Doppler flowmetryis reduced during high-intensity
exercise (> 80% VO2 x) (Smolander, Sago, & Korhonen, 1991).
Recently, however, Samra et al. (1996) have observed that intravenous infusion of
Epi caused significant elevations in adipose tissue blood flow and net outflow of fatty
acid from adipose tissue in humans. The in vivo infusion of Epi induced arterialized
plasma Epi levels of approximately 300 nel, which are similar to levels observed
during moderate- to high-intensity exercise (Romijn et al., 1993). It has thus been
suggested that the effects of Epi on adipose tissue blood flow and fatty acid transport12
are likely to be regulated by stimulation of p-adrenoceptors,rather than a-
adrenoceptors, located in the adipose tissue vasculature.
Most recently, a microdialysis technique has demonstratedthat nonselective
(propranolol) and P2-selective (ICI-118551) adrenergic antagonistsdecreased tissue
blood flow causing hypoglycemia-induced lipolysis (plasma glycerol)in in vivo human
skeletal muscle, whereas (1- selective antagonist (metoprolol) didnot affect both blood
flow and lipolysis (Hagstrom-Toftet al.,1998). Also, in the same study,f32-
adrenoceptor agonist (terbutalin) enhanced muscle blood flowand intramuscular
lipolysis, whereas Pi- (dobutamine)or f33-adrenoceptor (CGP-12177) agonists did not
influence those variables. A study by Abumradetal.(1986), who incubated rat
adipocytes with catecholamines (NEor Epi) or P-adrenergic agonist (isoproterenol),
has shown that p-adrenergicresponses to both NE and Epi facilitate fatty acid
mobilization by regulating fatty acid transport at the membrane ofadipocytes. Also,
the absence of in vitro effects of a-adrenoceptors agonists and antagonistson fatty
acid transport has been observed, suggesting that a-adrenergic inhibitiondoes not exist
in the rat adipose tissue. It should, however, be noted that theconcentrations of NE
and Epi used in the study by Abumrad et al. (1986)were pharmacological rather than
physiological.
Furthermore, van Baak et al. (1993) have discussed that fatty acid oxidation during
high-intensity exercise (70% of maximalpower output) is likely to be regulated b y
fattyacid transport mechanisms into human skeletal muscles.This transport
mechanism is possibly mediated by j3-adrenoceptors, since increasedplasma FFA
availability by infusing lipid and heparin did not alter respiratory exchange ratio after
p-adrenergic antagonists were administered. Thus, it is still unclear whetherreduced
FFA mobilization is caused by enhanced a.-adrenergic inhibition of adipose tissue
blood flow or of fatty acid transport system inresponse to large increases in circulating13
catecholamines (possibly NE; Ref Hjemdahl, & Linde, 1983) during high-intensity
exercise.
Threshold Increases in Plasma Catecholamines and Endogenous Opioid in
Relation to Blood Lactate Concentrations During Exercise
It is well established that exercise leads to increases in plasma catecholamines inan
intensity-dependent manner. Lactate threshold (LT) is well recognizedas an intensity
of exercise at which metabolic acidosisoccurs due to appearance of a significant amount
of lactic acid (Wasserman & Mcllroy, 1964; Wasserman, Whipp, Koyal, & Beaver,
1973). LT is conveniently determinedas the highest intensity which can be attained
without an abrupt increase in blood lactate levels during incremental exercise.
Catecholamines are observed to be secreted into the plasma inresponse to exercise.
Catecholamine secretion is reflected directly by the plasma levels since circulating
catecholamines are rapidly cleared or metabolized and their half-life isvery short
(Mannelli, Pupilli, Lanzillotti, Ianni, & Serio, 1990).
LT has been observed to correspond with an inflection point of increases in plasma
Epi (Chwalbinska-Moneta, Krysztofiak, Ziemba, Nazar, & Kaciuba-Uscilko, 1996;
Mazzeo & Marshall, 1989; Schneider, McGuiggin, & Kamimoru, 1992; Turner et al.,
1995) and NE (Chwalbinska-Moneta et al, 1996; Mazzeo & Marshall, 1989; Turner et
al., 1995) during incremental exercise. Mazzeo and Marshall (1989) have demonstrated
a threshold where both Epi and NE abruptly increased during the time courses of
incrementalcycling and runningtests(i.e.,catecholamine threshold)occurred
simultaneously with LT (r = 0.97 for Epi and 0.98 for NE). They have addressed the
mechanism that enhanced secretion of catecholamines beyond the thresholdappears to
stimulate muscle glycogenolysis and subsequently elevate lactic acid production and
blood lactate appearance.14
Likewise, Chwalbinska-Moneta et al. (1996) have reported that NE and Epi
thresholds (64.2 ± 5.0 and 62.3 ± 4.9% V02., respectively) during cyclingwere not
significantlydifferentfrom LT (62.9 ± 6.2% V02.) detectedbylog-log
transformation method. Also, Turner et al. (1995) have observed that LT during cycling
was not significantly different from NE and Epi (480 ± 146 pgm1-1) thresholds (64.6 ±
2.4, 62.5 ± 2.4, and 60.8 ± 4.3% VO2max, respectively). They also have reported that
- 1 an increase in plasma Epi concentrations by graded Epi infusions (0.02 ligkg -1 -mtn
every 5 minutes until a rate of 0.12 ttgle.min-1 was made) was significantly related to
an increase in blood lactate concentrations during below-LT intensity exercise where
plasma Epi levels did not increase.
However, Turner et al. (1995) have mentioned that even though increased plasma
Epi concentrations by Epi infusionswere similar to those observed during maximal
incremental exercise (1,429 ± 135 pgm1-1), the increase in blood lactate during Epi
infusions did not reach levels observed during maximal exercise. This indicates that
plasma Epi is not the only factor to causean increase in blood lactate. Also, Weltman
et al. (1994) have reported that although LT was significantly associated with NE and
Epi thresholds during running, it occurred at significantly lower exercise intensities than
NE and Epi thresholds (V02 = 3.76 ± 0.18vs. 4.04 ± 0.19 and 4.35 ± 0.14 1-min-1,
respectively; p < 0.05). They have reported that LTwas detected when plasma Epi
level was200 - 250 pg-m1-1.
Schneider et al. (1992) have mentioned that a casual relationship between LT (41%
V02.) and catecholamine (46- 47% V02.) thresholds during cycling indicates that
increases in plasma catecholamines are one of the determinants ofan increase in blood
lactate. However, they have also suggested thata reduction in blood/muscle pH
resulting from lactic acid production causes increases in plasma catecholamines. The
increases in plasma catecholamines during high-intensity exercise (65% VO2max) appear
to be caused by lower catecholamine clearance rate due to decreased blood flow as15
compared with that during low-intensity exercise (25% VO2max) (Leuenberger et al.,
1993). It should be noted that an elevation in plasma NE levels reflects high degrees of
sympathetic nerve activity, whereas that in plasma Epi indicates adrenal medulla
stimulation (Mannelli et al., 1990).
As well as plasma catecholamines, circulating 0-endorphin (B-EP), an endogenous
mu-receptor opioid peptide, which is believed to have natural analgesic and opiate-like
pleasure- and euphoria-producing properties (Eckert, 1988), is also observed to
increase during exercise in an intensity-dependent manner in humans (Colt, Ward law,
& Frantz, 1981; Donevan, & Andrew, 1987; Farrell, Kjaer, Bach, & Galbo, 1987;
Goldfarb,Hatfield,Potts, & Armstrong,1991; Rahkila, Hakala, Sahninen, &
Laatikainen, 1987; Rahkila, Hakala, Men, Salminen, & Laatikainen, 1988). Colt et al.
(1981) have early reported that althoughan "easy" run (6.4 - 12.8 km) at a self-
regulated comfortable pace did not significantly increase B-EP immunoactivity (11.8
1.8 to 17.6 ± 3.1 pgm1-1; p = 0.067), a "strenuous" run with maximal effort
significantly elevated B-EP immunoactivity level (8.2 1 1.03 to 28.0 ± 6.3 pg-m1-1; p =
0.008) after exercise in humans. However, they did not mention the intensities of those
runs. Farrell et al. (1987) have shown that arterialized plasma B-EP did not change at
60% VO2max as compared to that at rest, but significantly increased at 100 and 110%
VO2max during treadmill running (duration, 7, 3, and 2 minutes, respectively) in trained
and untrained individuals. They also have demonstrated that the response of B-EP to
exercise was significantly more prominent in trained than that in untrained individuals
during supra-maximal exercise. Moreover, Donevan and Andrew (1987) have
demonstrated that plasma levels of B-EP markedly increased during 8-minute cycle
exercise at intensities of 75 and 95% VO2x(27.1 ± 2.4 and 74.1 ± 8.6 pg-mtl,
respectively; p < 0.05), whereas no significant change in plasma B-EP from resting
level was observed at 25 and 50% VO2max (18.3 ± 1.3 pgm1-1).16
However, Goldfarb, Hatfield, Sforzo, and Flynn(1987) have reported that serum B-
EP levels were not significantly alteredduring incremental exhaustive exercise as
compared to basal level (25.3 pgmr1), andthat there was no significant correlation
between exercise intensity and B-EP levels.It should be noted, however, that their
resting B-EP levelsare relatively high compared to those in a study by Colt et al.
(1981) (25.3 vs. 8.2 to 11.8 pgm1-1) and havea large interindividual variation (12.5 to
49 pgm1-1). Goldfarb et al. (1991) haveshown that plasma B-EP levels were
significantly elevated from resting value (4.61± 0.25 pmo11-1 in trained and 4.03 =4:
0.23 pmo11-1 in untrained subjects) during 30-minuteexercise at 70% (10.48 ± 1.77
pmo111 in trained and 11.65± 1.19 pmo11-1 in untrained subjects) and 80% (18.08
3.21 pmo11-1 in trained and 20.65 ± 3.29 pmo1.1"1 inuntrained subjects) but not at 60%
VO2max.
The relationship between exercise intensity andplasma B-EP levels during resistive
exercise appears to be inconsistentamong several studies (Kraemer et al.,1996;
Kraemer, Patton, et al., 1989; Pierceet al., 1994). Kraemer, Patton, et al. (1989) have
reported that during cycle exerciseat 36, 55, 73, and 100% of maximal leg power
(duration, 189, 46, 16, and 6 seconds, respectively),corresponding to115, 175, 230,
and 318% VO2max, respectively, plasmaB-EP responses did not change even as
exercise intensity was increased, and significantlyincreased only at 36% of maximal leg
power. Pierce et al. (1994) have found that plasma B-EP levelswere significantly
decreased after resistance exerciseas compared with before exercise (4 exercises x 3
sets x 8 repetitions at 80% of one repetition maximum, RM) (10.5± 1.3 vs. 16.5 ± 1.2
pgm1-1). More recently, Kraemeret al. (1996) have also reported there was no
significant elevation in plasma B-EP after resistance exercise(4 exercises x 3 sets x 10
repetitions at 10 RM). It is suggested that the durationof exercise could also be of
importance in stimulating plasma B-EP.17
Plasma B-EP is observed to abruptly increaseat an exercise intensity associated
with lactic acidosis in humans (De Meirleiret al., 1986; McMurray, Forsythe, Mar, &
Hardy, 1987; Rahkila et al., 1988; Schwarz, & Kindermann,1990; Taylor et al., 1994).
De Meirleir et al. (1986) have observed that blood B-EP levelwas enhanced during
bicycle exercise at an intensity abovean arterial blood lactate level of 4 mM, whereas
B-EP level was unchanged during 1-hour submaximal exercise(< 70% predicted
maximal heart rate) below the blood lactate level. They havesuggested that B-EP
secretion would be triggered by the predominance of anaerobic metabolism, since there
was a significant correlation between blood lactate and plasma B-EP levels during
exercise.
Likewise, Rahkila et al. (1988) have demonstrated that plasma levels of B-EP andf3-
lipotropin (B-LPH), a prohormone of B-EP,were unaltered from resting values during
10-minute running at intensities of 50, 58, 69, and 80% VO2max (2.87± 0.58, 2.33 -±
0.55, 3.32 ± 0.38, and 3.49 ± 0.57 pmo114, respectively), whereas significant increases
in B-EP and B-LPH were observed during exerciseat intensities of 92 and 98% VO2max
(7.69 ± 1.20 and 20.4 ± 1.53 pmo11-1, respectively;p < 0.001). Also, the non-linear
relationship between exercise intensity and plasma levels of B-EP and B-LPHwas
accompanied by a non-linear increase in blood lactate levels (0.6± 0.1, 0.5 ± 0.1, 0.6 It
0.1, 1.4 -± 0.2, 4.3 ± 0.2, and 11.1 ± 0.5 mM at 50, 58, 69, 80, 92, and 98% VO2max,
respectively). Schwarz and Kindermann (1990) have revealed that plasmaB-EP did
not significantly increase untilexercise intensityexceeded individualanaerobic
threshold (synonymous with anaerobic threshold: Ref. Urhausen,Coen, Weiler, &
Kindermann, 1993). Several other studies also have showna significant correlation
between blood lactate and plasma B-EP levels during exercise (Kraemeret al., 1993;
Kraemer, Fleck, et al., 1989; Goldfarb, Hatfield, Armstrong, & Potts, 1990).
More recently, Taylor et al. (1994) have revealed that plasma B-EP levels during
exhaustive incremental exercise significantly correlated with indicators of acidosis such18
as blood pH (r = -0.94), PCO2 (r= -0.85), HCO3- (r = -0.88), base excess (r = -0.94),
and lactate (r = 0.89). Subsequently,they investigated the effect of bufferingon plasma
B-EP and blood lactate levels duringconstant-intensity exercise at 85% VO2max for 20
minutes. They observed that bufferingsuppressed acidosis by significantly elevating
blood pH to 7.4 from 7.3 (p< 0.0001). Interestingly, buffering also significantly
prevented the increase in plasmaB-EP during constant exercise (p < 0.0001), thus
indicating that acidosis associatedwith high-intensity exercise would bea primary
trigger for B-EP secretion. Thefinding suggests that a decrease in blood pH resulting
from lactic acid production wouldelevate plasma B-EP levelsas observed for plasma
catecholamines in a study by Schneideret al. (1992).
The relationship between plasmaB-EP and catecholamines levels during exercise
has been examined in humans (Bortzet al., 1981; Brooks et al., 1988; Dearman, &
Francis, 1983; McMurrayet al., 1987; Schwarz, & Kindermann, 1990). Bortzet al.
(1981) have reported that both bloodNE and B-EP increased during and aftera 100 -
mile run. McMurray et al. (1987) havedemonstrated that significant increases in levels
of plasma B-EPwere accompanied by significant increases in plasma NE and Epi
during 20-minute cycle exerciseat 80 (16.1 ± 4.0 pmo11-1, 2.00 ± 0.14 ng-ml"', 0.88±
0.07 ngm1-1, respectively) and 100%V02. as compared to those at 40 (3.8 ± 0.7
pmo11-1, 0.60± 0.05 ngral, 0.33 ± 0.03 ngm1-1, respectively) and 60% (6.3± 0.9
pmo11-1, 0.93 ± 0.07 ng.ml",0.49 ± 0.02 ngm1-1, respectively)V02.. Also, blood
lactate levels were observedto abruptly increase at 80% VO2max (9.5± 2.9 vs. 1.5
0.7 at 40%, 3.0 ± 1.2 mMat 60%). Schwarz and Kindermann (1989, 1990) have
examined responses of plasma B-EPand catecholamine to exercise intensity which
brought about lactic acidosis (i.e.,individual anaerobic threshold, IAT). They (1989)
have reported that linear increasesin plasma levels of NE and Epiwere observed
during 90-minute constant-intensitycycle exercise at IAT (63% VO2max), whereas
plasma B-EP significantly increased onlyat the 75th and 90th minute of the time19
course of exercise. However, they (1990) reexamined employingexhaustive incremental
exercise and reported that both plasmaB-EP and Epi significantly increased only after
an exercise intensity exceeded IAT (70% VO21ax). They thusconcluded that there
would be an interaction between B-EPand catecholamines during exercise.
In animal studies, f3-adrenergic stimulationby infusion of isoproterenol (Barna,
Sweep, Veldhuis, Wiegant, & De Wied,1990; Berkenbosch, Vermes, Binnekade, &
Tilders, 1981) and epinephrine (Berkenboschet al., 1981) caused an elevation in
plasma B-EP level in rats. Also, 13-adrenergicblockade (propranolol) inhibited B-EP
secretion from the pituitary lobes ofrats under restraint and ether stress (Kjaer,
Knigge, Bach, & Warberg, 1995).However, the effect of catecholamines on B-EP
secretion in humans is inconsistent with the findingsin animals (Oberbeck et al., 1996;
Troullos, Hargreaves, Goldstein, Stull, & Dionne,1989).
Administration of epinephrine in humans under localanesthesia reduced plasma B-
EP immunoreactivity inresponse to the mild stress (Troullos et al., 1989). Also, most
recently,Oberbeck etal.(1996) have shownthatintravenousinfusionsof
norepinephrine and epinephrine in humans failedto alter plasma levels of B-EP. The
plasma levels of NE and Epi after administrationwere approximately 2.3 and 0.85
ngm1-1, respectively, which couldbe observed during intense exercise (McMurray et
al., 1987).
It should be noted that circulating levels ofB-EP seem to be regulated separately
from central levels. It has been observedthat, in dogs, plasma B-EP levels were
significantly higher during high-intensity exercise thanduring low-intensity exercise,
whereas cerebrospinal fluid (CSF) levels of B-EPsignificantly increased during low-
but not high-intensity exercise (Radosevichet al.,1989). Also, increased plasma
catecholamine levels during exercisewere not significantly different between high and
low intensities, whereas NE in CSFwas significantly higher during high-intensity
exercise than during low-intensity exercise. It hastherefore been concluded that CSF B-
EP does not increase in proportionto exercise intensity and the plasma level of B-EP20
and that CSF B-EP appears to be derived from the brain during low-intensityexercise,
since crossover of B-EP from the plasmato the brain would be minimal due to the
blood-brain barrier. It has been evident that blood levels of B-EP donot appear to
reflect central nervous system (CNS)or CSF levels in rats (Rossier et al., 1977) and
humans (Nakao et M., 1980). Increased blood levels of B-EPwas observed in response
to foot shock in rats, whereas hypothalamus levels significantly decreased (Rossieret
al., 1977).
Thus, circulating and central levels of B-EPare likely to be regulated by separate
mechanisms and have different physiological roles between peripheral sites andCNS.
However, circulating B-EP in the bloodcan contribute to its CSF levels, but to much
less extent to the central levels (Banks, & Kastin, 1990). Significantpermeability of
circulating B-EP into brain regions of rats (Rapoport, Klee, Pettigrew, & Ohno,1980)
and hypothalamus of rabbits (Merin, Hollt, Przewlocki, & Herz, 1980)was observed.
It has been suggested that there would bea feedback mechanism between circulating
and brain B-EP, which has potential central effects and modulation in the secretioninto
the plasma, respectively (Rapoport et al., 1980). Interestingly, exercisestimulates
opiate receptors in the brains of rats to increase (Pert, & Bowie, 1979)or decrease
(Sforzo, Seeger, Pert, Pert, & Dotson, 1986) theoccupancy for endogenous opioids.
Involvement of Endogenous Opioids in Catecholamine Secretion and Fat
Metabolism During Exercise
The most potent opioid peptide, B-EP, is well establishedto increase in plasma
during exercise. The increase in circulating B-EP has been recognizedas a general and
holistic stress response of the organism toa variety of stimuli (Farrell et al., 1982;
Guillemin et M., 1977). In fact, plasma B-EP levels have been observedto increase
concomitantly with plasma adrenocorticotropin (ACTH) inresponse to various forms21
of stress such as exercise (Scavo, Barletta, Vagiri, & Letizia, 1991; De Meirleiret al.,
1986; Farrell et al., 1987; Fraioli et al., 1980; Guilleminet al., 1977; Oleshansky,
Zoltick, Herman, Mougey, & Meyerhoff, 1990; Rahkilaet al., 1987, 1988).
B-EP and ACTH both are formed in the anterior pituitary froma common precursor
peptide (proopiomelanocortin) and secreted peripherally from the corticotrophsof the
anterior pituitary into the circulation. It has been suggested thatstrenuous exercise
stimulates the hypothalamo-pituitary-adrenocortical axis viachemoreceptors in muscle
(Schwarz, & Kindermann, 1990; Taylor et al., 1994). It is possible thatsecretion of B-
EP and ACTH from the pituitary is stimulated by afferentnervous activity from
contracting muscles during exercise, since lumbar epidural anesthesia hasbeen observed
to abolish increases in plasma B-EP and ACTH during submaximal exercise in humans
(Kjaer, Secher, Bach, Sheikh, & Galbo, 1989). Also, B-EP cosecreted with ACTH from
the pituitary would be under opioidergic control, since opioidreceptor antagonism
augmented plasma B-EP secretion during exhaustive incremental exercise(Droste,
Greenlee, Schreck, & Roskamm, 1991). B-EP contents in the hypothalamus and
pituitary have been observed to decrease aftera 4-hour acute bout of swimming in rats
(Tendzegolskis, Viru, & Orlova, 1991). It should be noted, however, that central release
of B-EP and ACTH from the brain into CSF isnot reflected by plasma levels of those
peptides, since plasma B-EP and ACTH increased during low- and high-intensity
exercise in dogs, but CSF B-EP and ACTH did not increase during high-intensity
exercise (Radosevich et al., 1989).
Thus, increased levels of plasma B-EP isa stress response to such a stimulus as
exercise, which is indicated by a concomitant increase in plasma ACTH. Also, the
increase in plasma B-EP in response to exercise is likelyto be linked either directly or
indirectly toexercise metabolism(Farrell,1985).However, the physiological
significance for increased secretion of B-EP in plasma during exercise hasnot yet been
fully elucidated in humans. Also,a question still remains as to whether the peripheral22
effect of increased levels of plasma B-EP is mediated by activities of theperipheral
target organs.
Farrell (1985) has mentioned thatan exercise model is useful to establish the
understanding of the physiological significance for endogenous opioids inanimals and
humans. Also, employingan opioid antagonist with high affinity for mu-opioid
receptors, naloxone (NAL), is assumed to bea useful probe to clarify the roles for
endogenous opioids in metabolism atrest and during exercise in humans (Farrell, 1985).
Intravenous administration of NAL (10 and 20 mg) in resting humans causedsignificant
increases in plasma levels of ACTH and cortisol above basal levelscompared to
placebo trials (Volavka, Cho, Mallya, & Bauman, 1979). Grossman,Moult, Cunnah,
and Besser (1986) have reported that 25 of NAL significantly increased serum
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in males, but 6, 100,
or 250 Kg.kg-1 did not significantly affect. Also, only 250 pg,kg-1 of NAL caused
significant rises in serum cortisol and plasma ACTH. Moreover, another study has
shown that 10 mg of NAL elevated plasma Epi level in resting humans, whereas0.4 or
4.8 mg of NAL did not affect the plasma level (Mannelliet al., 1984). Thus, the effect
of NAL appears dose-dependent. It has been believed that endogenous opioidsexist as
a coordinator of the excessive activities in the hypothalamo-pituitary-adrenocortical
axis (Grossman, 1988).
In an early study employing exercise, McMurray, Sheps, and Guinan (1984) have
shown that an intravenous infusion of NAL (0.4 mgm1-1) significantly reduced maximal
minute ventilation and heart rate during exhaustive incremental exercise in females.
However, they have argued that the attenuated cardiorespiratoryresponses appeared
to be due to a direct agonistic effect, rather than antagonistic effect, of NAL.
There are numerous studies in which the hormonal significance of endogenous
opioids during exercise has been examined using NAL in humans. Grossmanet al.
(1984) have demonstrated in male subjects that exercise-induced increases in plasma
Epi and NE during 20-minute exercise at 80% V02.were further augmented by a high23
dose of NAL infusion (12.2 mgm1-1) compared with placebo trials (2.12± 0.3 vs. 1.04
0.15 nmo1.1-1 for Epi; 12.2 ± 1.0vs. 9.6 ± 0.7 nmo11-1 for NE, p < 0.05). These
effects were not present at rest and during exerciseat 40% VO2max. However, enhanced
catecholamines by NAL did not lead to significant changes in cardiorespiratory
variables. Also, they have observed that NAL enhanced exercise-induced increases in
serum cortisol, LH, prolactin and aldosterone during higher-intensity exercise.
A study by the same group (Lam, Grossman, Bouloux, Drury, & Besser, 1986) also
has shown that 8 mg of NAL augmented increasedresponse of plasma Epi to 5-minute
acute handgrip exercise (30% of maximal voluntary contraction)as compared to saline
trial (0.50 ± 0.15 vs. 0.24 ± 0.02 nmo11-1). The basal level of Epiwas not altered by
NAL. The similar effect of NAL on plasma aldosterone has also been observed in the
study. However, their finding ofan unchanged Epi by NAL in the resting condition is
inconsistent with the results by Mannelli et al. (1984), where 10mg of NAL enhanced
plasma Epi level in resting humans. Lam et al. (1986) have asserted that the subjects in
the study of Mannelli et al. (1984)were actually mildly stressed even at rest and
concluded that the NAL effecton catecholamine secretion mediated via the
sympathoadrenal system is detected in thepresence of stress such as exercise.
It has been indicated that the endogenous opioid system respondsto stress, but
does not have tonic modulation of hormonal and metabolic variables (Farrellet al.,
1986). Farrell et al. (1986) employedan oral administration of naltrexone, another mu-
opioid receptor antagonist, to investigate the influence of endogenous opioidson
hormonal responses during 30-minute cycling at 70% VO2max. They demonstrated that
the opioid antagonist significantly augmented exercise-induced increases in plasma
catecholamines (Epi and dopamine)as compared with placebo trials at 30 minute of
exercise (433 ± 100 vs. 207 ± 26 pg-m1-1 for Epi; 275-1- 144 vs. 131 ± 54 pg-mt 1 for
dopamine, p < 0.05). NE also tended to be reduced but not significantly (2012340
vs. 1562 ± 241 pg-ml-1). However, the augmented increase in catecholamine secretion24
during exercise was not accompanied byany significant alterations in cardiorespiratory
variables such as heart rate, systolic and diastolic bloodpressure, V02, respiratory
quotient (RQ), and ventilation. They have suggested that exercise-inducedsecretion of
catecholamines from the adrenal medulla is inhibited by endogenousopioids.
Circulating endogenous opioidsare likely to interact with the adrenal medulla, since
opioid receptors have been foundto exist in the adrenal medulla of bovine (Chavkin,
Cox, & Goldstein, 1979). Farrell, Ebert, and Kampine (1991)also have reported the
significant stimulatory effect of NAL (1.2 mg)on an exercise-induced increase in Epi
during 3-minute handgrip isometric exerciseat 25% of maximal voluntary contraction as
compared with placebo trial (48 ± 13vs. 28 ± 4 pgmr1). Moreover, they have
demonstrated that sympatheticnerve activity detected by peroneal nerve recordings
during isometric exercisewas further enhanced by NAL, thus suggesting an inhibitory
role for endogenous opioidson sympathetic nerve activity induced by muscle
contraction. More recently, Angelopoulosetal.(1995) have demonstrated that
increases in plasma levels of NE and Epi inresponse to prolonged intense exercise
(80% VO2max) were further enhanced by administration ofNAL (1.2 mg) as compared
to placebo trials in humans (24 ± 2.2vs. 20 ± 1.7 nmol1-1 for NE; 1679 ± 196 vs. 1196
J.:155 pmo1-1-1 for Epi). The enhanced increases in catecholaminesby NAL were
accompanied by an augmented increase in blood lactate, thussuggesting enhanced
catecholaminergic stimulation to glycolysis and glycogenolysis.
Thus, endogenous opioids appear to be involved in the sympathoadrenalregulation
of catecholamine release in the plasma during exercise.However, whether the
involvement of endorphins in catecholamine release is mediated bya central or
peripheral mechanism has not yet been established. Farrellet al. (1991) have suggested
that the endogenous opioid system interacts with ascendingmessages from working
muscles in the spinal cord and modulates the peripheral neuroendocrinesystem (e.g.,
adrenal medulla) by efferent sympatheticnerves.However,directopioidergic
modulation via motor centers in the CNS (central command) is alsoa possible25
mechanism of the interaction between opioids and neuroendocrine andsympathetic
nervous activities (Kjaer et al., 1989), since NAL can cross the blood-brain barrier. In
an in vitro study using rats,it has been demonstrated that NE release from A2
noradrenergic nucleus located in the caudal dorsomedial medulla ofrats was inhibited
by B-EP, but not by other opioid receptor (e.g., delta and kappa) agonists,and the
inhibitory effect was reversed bya mu-opioid receptor antagonist (Can, 1997).
In animal studies, central administration of B-EP enhanced catecholamine secretion
(May, Whitehead, & Mathias, 1991; Van Loon, Appel, & Ho, 1981). VanLoon et al.
(1981) have observed that intracisternal administration of B-EP increasedplasma
catecholamine concentrations (i.e., NE, Epi and dopamine) in consciousrats and that
the effects of B-EP were reversed by systemic administration ofNAL. They have
suggested that central sympathetic outflow to both adrenal medulla and sympathetic
nerve endings is stimulated by B-EP. Likewise, May et al. (1991) have reported that
intracerebroventricular administration of B-EP increased plasma NE and Epi in
conscious rabbits and that the effectswere reversed by intravenous NAL. Also, an
increase in mean arterialpressure was accompanied by the B-EP-induced increases in
plasma catecholamines and prevented by a-adrenoceptor blockades (prazosin and
yohimbine).Ithastherefore been suggested that B-EP centrallystimulates
periventricular mu-opioid receptors to enhance Epi secretion from the adrenal medulla
and sympathetic nerve activity (i.e., NE release), resulting in vasoconstriction mediated
via a-adrenoceptors. Those results from animal studies (Mayet al., 1991; Van Loon et
al., 1981) are opposite to the addressed inhibitory role for endorphins in the release of
catecholamines in exercising humans (Farrell et al., 1986, 1991; Grossmanet al., 1984;
Lam et al., 1986). Nevertheless, it could be explained that the inhibitory role for
endorphins is mediated by a peripheral mechanism (Farrellet al., 1986), while the
stimulatory role is involved in a central mechanism.
Itis possible that circulating endogenous opioid peptides in plasma havean
inhibitory role for catecholamine secretion inresponse to prolonged exercise in humans26
(Farrell et al., 1986, 1991; Grossman et al., 1984; Lam et al., 1986). It has therefore
been mentioned that one of the significantpurposes of increased levels of circulating
endogenous opioids (e.g., B-EP) would be to prevent excessive sympathoexcitation
beyond that needed to meet the metabolic and cardiorespiratory demands duringsuch a
stress as exercise (Angelopoulos et al., 1995; Farrell et al., 1991; Thoren, Floras,
Ho Hann, & Seals, 1990). However, there is also evidence that NAL (0.86- 1.08 mg)
failed to augment increases in plasma catecholamines during 10-minutecycling at 50%
and 80% of maximal power output in healthy males (Bramnert, & Hokfelt, 1985).
Also, a large dose of NAL (10 mg followed bya continuous infusion of 10 mg.hr-1) did
not significantly alter plasma NE level at 30% and 60% of maximalpower output
during 3-minute stage incremental cycling exercise (Staessenetal.,1985). The
discrepant findings among those studies examining the NAL effecton plasma
catecholamine levels are likely due to relatively short duration and/or low intensity of
exercise, which could not have attaineda metabolic steady state to activate the
endogenous opioid system (Angelopoulos et al., 1995).
Taken together, B-EP (opioid peptides) is likely to, in turn, influence lipolysis,
since opioid peptides appear to affect lipolytic (catecholamines and glucagon) and anti-
lipolytic (insulin) hormones in response to exercise. B-EP has been shownto stimulate
insulin secretion from in vitro pancreas of resting dogs, and the increased levels of
insulin were attenuated by NAL (Ipp, Dobbs, & Unger, 1978). Also, NAL diminished
plasma insulin response to hyperglycemia 30 minutes after exercise inrats (Farrell,
Sonne, Mikines, & Galbo, 1988). Bouix, Najimi, Lenoir, Kerdelhue, and Orsetti (1996)
have found that 2.5 hours of swimming causeda significant increase in plasma B-EP in
rats and reduced response of in vivo plasma insulin to intravascular glucose injection.
However, the reduced response of insulinwas further blunted by intraperitoneal
injection of NAL. Also, they have observed that B-EP added to in vitro incubatedrat
islets enhanced insulin secretion inresponse to glucose and that the effect of B-EP was
antagonized by NAL. The presence of B-EP enhanced glucose uptake bymouse27
diaphragm muscle, and the effectwas augmented by contracting the muscle (Evans,
Khan, & Smith, 1997). On the contrary,an intravenous infusion of B-EP enhanced an
exercise-induced decrease in plasma insulin and increase inplasma glucagon levels
during exercise in rats, althoughan infusion of NAL did not reverse the effects
(Fatouros, Goldfarb, Jamurtas, Angelopoulos, & Gao, 1997).
In fasting humans, intravenous administration of B-EP causedsignificant elevations
in plasma insulin and glucagon (Reid, & Yen, 1981). Also,since adrenergic activity (a2)
causes inhibition of insulin secretion (Boyd et al., 1974), itis probable that B-EP
would play a role of facilitating insulin secretionindirectly by inhibiting a2-adrenergic
modulation. More recently, Angelopoulos, Robertson, Goss, andUtter (1997) have
observed that 1.2 mg of NAL administration bluntedan exercise-induced increase in
plasma glucagon levels during 20-minute exerciseat 80% VO2ma in humans, whereas
NAL failed to alter a change in plasma insulin levels. It has thusbeen indicated that
endogenous opioids augment plasma glucagon during high-intensityprolonged exercise.
However, they did not examine the effect of NALon any variables of plasma substrate
responses during exercise. Also, they have noted that unaltered levels of plasma insulin
by NAL would indicate that critical pharmacological levels of plasmaopioids, as
observed in a study by Reid and Yen (1981) (1000-fold the basal level),are required to
stimulate insulin secretion from thepancreas (Angelopoulos et al., 1997).
Vettor, Manno, De Carlo,and Federspil(1987) examined theeffectof
administration of NAL on plasma FFA and glycerol in 60 minutes of forcedswimming
in rats. They have revealed that exercise induced increases inplasma FFA and glycerol,
whereas NAL attenuated the exercise-induced increase in those plasmasubstrates.
They therefore concluded that endogenous opioids would beinvolved in exercise-
induced lipolysis in rats. It could thus be assumed thata reduction in exercise-induced
increases in plasma FFA and glycerol by opioidreceptor antagonism is attributed to
the enhanced inhibitory effect of catecholamineson fat mobilization during forced
swimming (Vettor et al., 1987). Also, intravenous administration ofB-EP increased28
plasma FFA and glycerol in rabbits, and the opioid-stimulated in vivo lipolysiswas
reduced by the presence of NAL (Richter, Kerscher, & Schwandt, 1983). In in vitro
studies, opioid peptides (B-EP, B-LPH, enkephalins, etc.) have been shownto have
lipolyticproperties,in isolated rabbit adipocytes (Jean-Baptiste, & Rizack, 1980;
Richter, & Schwandt, 1983, 1985). However, the opioidergic mechanism regulating
lipolysis would be more complicated in humans, since the adrenergic modulation in
lipolysis is dependent on both types of receptors (i.e.,a and (3 receptors) (Savard et
al., 1987).
In humans, Farrell et al. (1986) have reported that despite additionally increased
levels of plasma Epi, naltrexone did not significantly influenceserum levels of FFA and
RQ during and after prolonged cycling (30 minutes) at 70% VO2ma,. Plasma insulin and
glucagon levels were not changed by naltrexone during exercise. Also, Kjaeret al. (1989)
have observed that although lumbar epidural anesthesia abolishedan increase in plasma
B-EP during submaximal exercise (55% VO2max) in humans, plasma concentrations of
glycerol, and FFA and RQ were not significantly altered. It should be noted, however,
that plasma catecholamines (NE and Epi), insulin, and glucagonwere also unchanged b y
the sensory blockade. They therefore concluded that fat metabolism would be regulated
by direct stimulation of neuroendocrine mechanisms from motor centers in the brain
(probably NE and/or Epi) during exercise, rather thannervous feedback from muscle
stimulated by circulating B-EP. However, it still remains unclear whether endogenous
opioid peptides enhance lipolysis during exercise in humans, since B-EP has indeed
been shown to stimulate insulin and inhibit catecholamine secretion. Also,itis
uncertain whether the involvement of B-EP in exercise-induced lipolysis is affected by
exercise intensities.
On the basis of all of the above, the suppressed plasma FFA mobilization observed
during high-intensity exercise might result from accelerated a2-adrenergic activity due
to very high levels of circulating catecholamines (Hjemdahl, & Linde, 1985; Hodgetts et
al., 1991; Kanaley et al., 1995; Romijn et al., 1993). Therefore, the inhibitory role of29
opioid peptides in the control of catecholamine secretion during intense exercise would
be to mitigate a2- adrenergic reductions in fat mobilization. However, in spite of
opioidergic inhibition in catecholamine secretion, the influence of opioid peptides
would be masked by overwhelming sympathoexcitatory afferent commands from
central and peripheral systems during prolonged intense exercise (Allen, 19.83; Thoren
et al., 1990). This, in turn, leads to increases, rather than decreases, in plasma levels of
catecholamines and a decrease in fat mobilization during high-intensityexercise.
Furthermore, there is evidence that an increase in arterial plasma lactate levels observed
during intense exercise results in suppression in exercise-induced increases in plasma
FFA and glycerol (Boyd et al., 1974), despitea fall in plasma insulin, suggesting a
direct anti-lipolytic effect of plasma lactate.
Summary
Asexerciseintensitiesareincreased,plasma FFAmobilizationdeclines
progressively with concomitant increases in plasma catecholamines. (Romijnet al.,
1993). Endogenous opioid peptides (i.e., B-EP)appear to inhibit catecholamine
secretion during prolonged exercise in humans. During mild to moderate exercise, the
inhibition of catecholamine secretion would be minimal due toa small increase in
plasma B-EP at intensities below LT. During intense exercise at intensities above LT,
plasma B-EP level is augmented to increase, and catecholamine secretion would be
inhibited to a larger extent. However, sympathoexcitatory activity of central command
is enhanced during high-intensity exercise and thus overwhelms the effect of the
increase in plasma B-EP. The net effect observed during high-intensity exercise is
indeed an increase in circulating catecholamine levels (Thorenet al., 1990).
Also, even small increases in catecholamine levels during low-intensity exercise
below LT could facilitate lipolysis via 13-adrenoceptors, because lipolysis in adipose30
tissue is sensitive enough to the small increases in circulating catecholamines in humans
(Galster et al., 1981; Romijn et al., 1993). In fact, lipolysis has been observed tooccur
at plasma Epi levels in the range of 75 to 125 pgm1-1, whereas a threshold change in
blood lactate occurred at plasma Epi levels in therange of 150 to 200 pg-m1-1 (Galster
et al., 1981). On the other hand, large increases in circulating catecholamines would
inhibit fat mobilization due possibly to a2-adrenergic activity, reducing adipose tissue
blood flow. Therefore, even if B-EP playsa lipolyticrole during exercise, a
sympathoexcitatory influence overwhelms the effect of B-EPon lipolysisand
catecholamine secretion, when intense exercise is performed.
Employing NAL administration is assumed to be an appropriate probe to unmask
endocrine and metabolic roles of opioid peptides during exercise and determine whether
opioid peptides are involved in lipolysis and/or fat metabolism. Also, performing
different intensities above and below LT, in addition to NAL administration, could be
an effective means to establish whether opioidergic and adrenergic regulation in
lipolysis and fat mobilization differs between low- and high-intensity exercise.
It was hypothesized that NAL further would augment the increases in plasma levels
of catecholamines during exercise above LT. Also, itwas hypothesized that the effect
of NAL on plasma catecholamines would lead toa reduction in FFA mobilization into
the circulation possibly due to an inhibitory adrenergic mechanism during exercise
above LT. On the other hand, the effect of NAL would be unchangedor minimal during
exercise below LT. No previous study has been conducted to investigate the effects of
NAL on plasma levels of catecholamines and fat metabolism in relation to exercise
intensities above and below LT during prolonged exercise in humans.31
Statement of the Purposes
The purposes of the present study were: (a) to investigate the effects of opioid
receptor antagonism using NAL on plasma concentrations of catecholamines (NE and
Epi), glycerol (as an index of lipolysis), and FFA, and fatty acid and CHO oxidation
(indirect calorimetry), and (b) to determine the effect of two different intensities, above
and below LT, on the responses of hormones and substrates to opioid receptor
antagonism during prolonged cycling in trained males.32
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Abstract
This investigation was undertaken to determine the effects of an opioid antagonist,
naloxone, on plasma norepinephrine, epinephrine, glycerol, and free fatty acids (FFA)
and fatty acid and carbohydrate oxidation during exercise aboveor below lactate
threshold (LT) in trained males. 20 trained males (24.1 th 4.4yr; VO2peak, 62.7 th 6.0
ml-kg-1 -min-1) were randomly assigned to perform 30-minute cyclingat an intensity
either 10% above or 10% below LT. Each subject completed two exercise trials at the
assigned intensity with either naloxone (1.2 mg)or saline placebo administration in a
double-blind, counterbalanced order. Plasma norepinephrine was significantly higher
during exercise above LT than below LT (P < 0.05). Naloxone did not significantly
influence_ plasma catecholamine levels during exercise either aboveor below LT. Plasma
levels of glycerol and FFA during exercise did not differ between the two intensities.
Naloxone failed to produce significant differences in plasma glycerol or FFA either
above or below LT compared to the placebo trial. Fatty acid oxidation during exercise
was identical between the two intensities, whereas carbohydrate oxidation was
significantly higher above LT than below LT (P < 0.05). Naloxone did not significantly
alter fatty acid and carbohydrate oxidation either above or below LT. During exercise
10% above or 10% below LT, endogenous opioids may not play regulatory roles in
catecholamine secretion and substrate metabolism. Enhanced carbohydrate oxidation
contributed to elevated energy demands during exercise above LT.
Key words: Endogenous opioids- Naloxone- Plasma free fatty acids- Plasma glycerol
Introduction
The contribution of endogenous substrates to energy production during exercise is
largely associated with exercise intensities. According to the "crossover" concept by34
Brooks and Mercier (1994), the relativeenergy contribution of carbohydrate (CHO)
and fat utilization changes along the continuum of exercise intensities.Below a certain
exercise intensity (i.e., "crossover" point), fat oxidation predominates, and abovethat
intensity CHO utilization predominates toan increasing extent as exercise intensities
increase. Also, the shifts in energy substrate mobilization and utilizationare believed to
occur in association with lactate threshold (LT) (Brooks and Mercier 1994; Kanaley et
al. 1995).
Exercise leads to increases in plasma catecholamines inan intensity-dependent
manner, that are associated with the LT (Chwalbinska-Moneta et al. 1996; Mazzeo and
Marshall1989; Turner etal.1995; Weltman etal.1994).Itis known that
catecholamines have both facilitatory and inhibitory effectson lipolysis in human
adipocytes(Wahrenberg etal.1987,1989).Increasesinplasmalevelsof
catecholamines promote lipolysis via 13-adrenergic stimulation during exercise, whereas,
at high intensities of exercise, high levels of plasma catecholamines inhibitfat
mobilization into the circulation via a-adrenergic modulation (Hjemdahl and Linde
1983; Hodgetts et al. 1991; Kanaley et al. 1995; Romijn et al. 1993). It is therefore
suggested that circulating catecholamines during exercise would produce different
regulatory effects on fat mobilization between intensities above and below LT. Romijn
et al. (1993) have demonstrated that plasma levels of catecholamineswere significantly
increased with increasing exercise intensities (25to 65% VO2max), and the rate of
appearance of free fatty acids (FFA) was significantly decreased. Kanaley et al. (1995)
have also reported that, during prolonged running,an exercise intensity above the LT
blunts an increase in FFA mobilization (rate of FFA appearance)as compared with
below the LT.
13-endorphin (B-EP), an endogenous opioid, is also known to abruptly increaseat an
exercise intensity associated with lactic acidosis (i.e., LT) (De Meirleiret al. 1986;
Donevan and Andrew 1987; McMurray et al. 1987; Rahkila et al. 1988; Tayloret al.
1994). It is documented that endogenous opioid peptides havean inhibitory role for35
catecholamine secretion in response to prolonged intense exercise (Angelopoulos et al.
1995; Farrell et al. 1986; Grossman et al. 1984). In humans, administration of naloxone
(NAL), a mu-opioid receptor antagonist, further enhances increasesin plasma
catecholamines during prolonged high-intensity exercise (80% V02.), (Angelopoulos
et al. 1995; Grossman et al. 1984) but not during low-intensity exercise (40% VO2max)
(Grossman et al. 1984). It has been demonstrated that NAL attenuates exercise-induced
increases in plasma levels of glycerol and FFA in rats (Vettor et al. 1987), suggesting a
lipolytic influence of endogenous opioids. However, in humans, Farrell et al. (1986)
have reported that although naltrexone,another mu-opioid receptor antagonist,
augmented increases in plasma catecholamine levels during prolonged cycling at 70%
V02., serum levels of FFA and respiratory quotient (RQ) were not significantly
altered. As a result, the interaction among endogenous opioids, catecholamines, fat
metabolism, and exercise intensities is not fully understood at this time.
The purposes of this study were to determine whether NAL influenced plasma
catecholamines and, in turn, substrate metabolism during exercise and whether the
effect of NAL differed between exercise intensities above and below LT in trained
males.
It was hypothesized that NAL would further augment the increases in plasma levels
of catecholamines during exercise above LT, since significant increases in plasma
catecholamines and opioid peptide (i.e., B-EP) concomitantly occur during exercise
above LT (McMurray et al. 1987; Schwarz and Kindermann 1990). Also, it was
hypothesized that the effect of NAL on plasma catecholamines would lead to a
reduction in FFA mobilization into the circulation, possibly due to an inhibitory
adrenergic mechanism during exercise above LT, where shifts in substrate metabolism
occur (Kanaley et al. 1995). On the other hand, the effect of NAL would be minimal
during exercise below LT. No previous study has been conducted to investigate the
effects of NAL on plasma levels of catecholamines and on fat metabolism in relation to
exercise intensities above and below LT during prolonged exercise in humans.36
Methods
Subjects
Twenty healthy trained males participated in the present study. The subjects had
been involved in systematic strenuous physical activity for at least one year prior to
participating in this study. Their physical activities included competitive road and
mountain cycling and triathlon.
The subjects were randomly assigned to cycle at a constant workload corresponding
to a V02 either 10% above (ALT, n = 10) or below (BLT, n = 10) their individual LT.
Physical characteristics of the subjects in BLT and ALT are listed in Table 1. There
were no significant differences in age, height, weight, body fat, VO2peak, and LT
between the two groups.





Age (yr) 25.7± 5.1 22.5± 3.1
Height (cm) 178.3± 8.9 179.4± 6.9
Weight (kg) 76.2± 6.2 73.9± 7.0
Body fat (%) 11.8± 6.3 11.8± 4.2
NTO2peak
(mi kg-1. min-i) 62.7± 7.6 62.7± 4.4
(F min-1) 4.7± 0.6 4.6± 0.3
Lactate threshold
Power output (W) 205± 39 201± 27
V02 (ml 39.6± 4.7 39.8± 3.6
VoN/02peak 63.4± 4.9 63.5± 4.0
Values are means ± SD.37
Each subject received an explanation of the protocol, read and signed an informed
consent, and completed a medical clearance (see Appendix A) prior to his participation
in this study. None of the subjects had taken any medications or hormone therapy,
except one subject who had taken an anti-seizure medicine daily for many years, and
none had any history of endocrine disorders for at least 6 months prior to participating
in this study. Also, none of the subjects were physically dependent on opioids,
postoperative patients, or patients with cardiac abnormalities.
The protocol of the present study was approved by the Institutional Review Board
for the Protection of Human Subjects of Oregon State University (see Appendix B).
Experimental protocols
Each subject visited the exercise laboratory on three separate occasions: (1) a
preliminary test for assessment of body composition and determination of LT and
peakexercisecapacity(VO2peak)during exhaustiveincrementalexercise,and
experimental tests for determination of the effects of (2) NAL and (3) saline placebo
(PLC) on plasma concentrations of NE and Epi and fat metabolism during constant
exercise at an intensity either above or below LT.
During the peak exercise capacity test on a rate-independent, electrically braked
bicycle ergometer (Ergoline SMC 800s, Sensormedics), the workload was increased b y
25 watts every 3 minutes until the subject obviously exceeded LT based on the
readings of blood lactate concentrations, and then every 1 minute until volitional
exhaustion. The initial workload was set at 100 watts. Blood samples were drawn in
the last 20 seconds of every 3-minute stage until LT was observed to be exceeded.
Throughout the exercise test, the subject's expired gas was continuously sampled into
a mixing chamber of an automated metabolic cart (System 2900, Sensormedics) for the
determination of VO2peak. Heart rate was monitored throughout the exercise test.38
At least 7 days after completing the peak exercise test, the subjects performed two
submaximal constant cyclingexercise testsatthe assigned intensitywith an
intravenous injection of either NAL or PLC in a double-blind, counterbalanced order.
Each exercise session was separated by at least 7 days and conducted in the morning
following an overnight fast to minimize a possible influence of diurnal variations on
hormonal concentrations. The subjects were instructed to maintain a normal lifestyle,
including their daily physical training regimens and a liberal and constant diet to
maintain their body weight and fat mass throughout the course of this study. The
subjects were instructed to refrain from consumption of nicotine, caffeine, and alcohol
and strenuous physical activities for 48 hours before each visit to the laboratory. Diets
and physical activities within the previous two days before each session were recorded
by a questionnaire. Their diets within two days prior to experimental tests were
relatively constant between the two successive exercise tests.
Thirty minutes before the start of each exercise test, an indwelling Teflon catheter
(18-gauge, Becton Dickinson, Sandy, UT) was inserted into a radial vein of the left
forearm and kept patent with an infusion of 0.9% NaCl.
The experimental protocol is illustrated in Figure 1.
After the catheterization, the subjects remained seated for approximately10
minutes. Subsequently, the subjects were moved to the bicycle ergometer and sat
quietly for additional 20 minutes (i.e., the subjects were rested for30 minutes).
Approximately 10 ml of venous blood was withdrawn into a 10-m1 Vacutainer tube
(Becton Dickinson)containingethylenediaminetetraaceticacid (EDTA) asan
anticoagulant at 15 and -5 minutes during resting and at 10, 20, and 30 minutes during
the constant exercise test.
After the first blood collection at minute -15 (control sample), the subjects were
injected with a bolus dose (3 ml) of NAL or PLC (0.9% NaC1) through the catheter
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Fig. 1 Experimental protocol. ALT, above lactate threshold; BLT, below lactate
threshold; NAL, naloxone trial; PLC, placebo trial. LT, lactate threshold
was collected. The subjects then commenced a 5-minute warm-up period and
subsequently the constant exercise test at their assigned workload corresponding to
V02 either 10% above or below LT. The subjects cycling below LT performed for 30
minutes, and those cycling above LT performed for 30 minutes or as long as the
subjects could keep pedaling at the assigned intensity, whichever occurred first.40
Materials and assays
1.2 mg of an opioid receptor antagonist, NAL (Naloxone HC1; Astra, Westborough,
Massachusetts), was preparedin3 ml of 0.9% salinesolutionproviding a
concentration of 0.4 mgm1-1 for an intravenous injection (Angelopoulos et al. 1995).
Blood lactate concentrations were determined with an automated lactate analyzer
(1500 Sport, Yellow Spring Instruments, Yellow Springs, OH). Percent changes in
plasma volume were estimated from hematocrit and hemoglobin concentrations (Hb)
by a method of Dill and Costill (1974). Hb concentrations (g-100 m1-1) were
determined spectrophotometrically using the cyanmethemoglobin method. The plasma
concentrations of hormones and substrates reported below were corrected for changes
in plasma volume.
Plasma was separated by centrifugation at 3,000 rpm for 15 minutes at 4 °C. 3 ml
of plasma for determination of plasma catecholamines was portioned into three of 1-ml
cryogenic tubes containing 5 mM reduced glutathione (50 pl of 0.1 M glutathione in 1
ml of plasma) as a protease inhibitor and gently shaken. The remainder of the plasma
was used for plasma FFA and glycerol measurements. The plasma samples were
immediately stored in aliquots in a freezer at -75 °C until analyzed within 6 months.
The determination of plasma catecholamine concentrations (NE and Epi) was
performed using high-performance liquid chromatography (LC-10AD solvent delivery
module,SIL-10Aautoinjector,SCL-10systemcontroller,Shimadzu)with
electrochemical detection (L-ECD 6A, Shimadzu) by a procedure modified from
Weltman et al. (1994) (See Appendix C). The limit of detectability for both NE and
Epi were 0.6 and 0.5 nM, respectively. The within-day coefficients of variation for NE
and Epi were 8.9 and 13.0%, respectively (n = 4). The between-day coefficients of
variation for NE and Epi were 9.8 and 10.8%, respectively (n = 12).41
Plasma glycerol concentrations (mM) were determined spectrophotometrically
(Beckman) in duplicate with an assay kit using an enzymatic method (Procedure No.
337, Sigma Chemical).
Plasma FF A concentrations (mM) were measured in duplicate with an assay kit
using an enzymatic colorimetric technique (NEFA-C, Wako Chemicals) with a
spectrophotometer (Beckman). The within-day coefficients of variation was 3.8% (n =
3). The between-day coefficients of variation was 6.2% (n = 6).
Analyses and calculations
LT (watts) was subjectively determined as a point of intersection of two linear
components which had different slopes: i.e., the highest workload which a subject can
attain without an abrupt elevation in blood lactate concentrations above baseline during
an incremental exercise test (Wasserman and Mcllroy 1964; Wasserman et al. 1973).
VO2 (ml.kg-1-min-1) corresponding to the LT was determined to establish the VO2 10%
above and below the individual VO2 at LT. Those values were maintained during the
trials by monitoring V02, and adjustment to the workload was made if necessary.
Indirectcalorimetryofsubstrateoxidationrateswasdeterminedusing
stoichiometric equations (Frayn 1983; Romijn et al. 1993). Nitrogen excretion rate was
assumed to be constant (135 µgkg body weight-1min-1) (Romijn et al. 1993). Fatty
acid oxidation (molkg body weight-1.min") was determined by converting the rate of
total fatty acid oxidation (triglyceride oxidation) (g-kg-1.min-1) to its molar equivalent.
The molecular weight of triglyceride was assumed to be 861 g-mor 1 (Frayn 1983).
Therefore, fatty acid oxidation was calculated by multiplying the molecular rate of
triglyceride oxidation by three, since each molecule of triglyceride has three moles of
fatty acid (Romijn et al. 1993). CHO oxidation (wnolkg body weight-1-min 1) was
determined by converting to its molar equivalent. The molecular weight of CHO was
assumed to be 180 gmorl (Frayn 1983).42
Body composition was estimated via hydrostatic weighing following the method of
Bonge and Donnelly (1989). Percent body fat was estimated by the generalized
formula by Ski. Residual lung volume was estimated from age and height using a
computer program (Metcalc, Human Kinetics, Champaign, IL).
Statistical analyses
All statistical analyses were performed using the Statistical Package for the Social
Sciences (SPSS for Windows 95, Ver. 7.5). The data obtained from pre- and post-
treatment constant exercise tests are given as means and the standard deviations.
Student's t-tests for independent samples were performed to compare the two
groups for age, height, weight, body fat,.VO2peak, and LT.
A two (exercise intensities) by two (trials) by five (time points of measurement)
between/within analysis of variance with repeated measures on the last two factors,
employing a multivariate approach, was conducted to assess mean differences for each
dependent variable separately with identical time points during exercise: When
significant F ratios were identified, a post hoc comparison using a Scheffe test was
applied to specific time points to locate where the significant differences had occurred.
A P < 0.05 level (two-tailed) was considered statisticallysignificant for all
statistical analyses.
Sample size
The treatment effect was expected at least as large as the selected population's
estimated standard deviation of each treatment group. According to a table for
determining the sample size (Potvin and Schutz 1996), ten subjects in each group were
required to achieve statistical power of 0.70 for detecting an interaction effect size of
0.80 with a set at 0.05.43
Results
Physiological responses
Workloads at which the subjects performed were significantly different between
groups (Table 2). The subjects in ALT actually exercised at V02 9.0% above their
individual V02 at LT (i.e., 43.4 ml kg-lmin-1), whereas those in BLT exercised at V02
14.9% below their individual V02 at LT (i.e., 33.7 ml lemin-1). Those were
corresponding to 69.2% and 53.9% VO2peak, respectively. The subjects in the two
groups completed 30-minute exercise tests for both NAL and PLC trials, except one
subject in ALT who achieved only 20 minutes of exercise for PLC trial.
A description of the physiological responses (i.e., heart rate, V02, % VO2peak, and
blood lactate concentrations) over time during exercise below and above LT for NAL
and PLC treatment trials is presented in Table 2.
No significant differences in these variables were found at control (i.e., pretest) and
baseline (i.e., minute 0) between groups for either NAL or PLC trial. Heart rate, V02,
and % VO2peak followed expected increases above baseline at the onset of exercise and
were maintained throughout exercise. Blood lactate concentrations were significantly
elevated from baseline during exercise for both trials in ALT but not in BLT, except at
minute 10 for NAL trial. Blood lactate concentrations were maintained throughout
exercise in both groups. Heart rate, V02, and blood lactate levels during exercise were
significantly greater in ALT than in BLT for both trials. No significant difference was
found between control and baseline values within each trial in both groups. Also, none
of these variables were significantly different at any measurement time point between
the NAL and PLC trials for either BLT or ALT, indicating that the administration of
NAL did not significantly influence heart rate, V02, and blood lactate levels.44
Table 2 Exercise test characteristics.
Below Lactate Threshold Above Lactate Threshold
NAL (N=10) PLC (N=10) NAL (N=10) PLC (N=10)
Workload (W)
Heart rate (beats.mircl)
180± 33 228±29 §
Pretest 63.8* 9.7 66.3 ± 10.8 73.7 ± 5.1 71.7 ± 7.7
Minute 0 63.2 ± 11.1 64.9 ± 10.4 72.1 ± 7.0 70.6 ± 8.4
Minute 10 131.7 ± 12.2 b 132.0 * 17.6b 158.4 * 10.1b 159.1 ± 10.9"
Minute 20 131.7± 12.2b 134.3 ± 18.3b 162.6 ± 11.7b '*163.7 ± 10.9"
Minute 30 134.2 ± 13.8b 136.7 ± 19.1b 167.1 ± 12.7b '*166.8 ± 12.4"
V02 (ml.kg-Linin-1)
Pretest 4.0 ± 0.5 4.2 ± 0.7 4.2 ± 0.3 4.4 ± 0.9
Minute 0 3.9 ± 0.3 4.4 ± 1.0 4.2 ± 0.4 4.5* 1.0
Minute 10 33.2 ± 5.3 b 33.3 ± 6.6b 42.1 ± 4.9 b.* 43.0 ± 4.1b,#
Minute 20
Minute 30
33.8 ± 5.4 b
34.0 ± 5.3 b
33.9 ±6.1b
34.1 ± 6.0b






Pretest 6.5 ± 0.6 6.7± 1.1 6.7 ± 7.1 ± 1.5
Minute 0 6.3 ±0.5 7.1 ± 1.9 6.8 ± 0.8 7.2* 1.5












71.1 ± 5.8 "
Blood lactate (mM)
Pretest 0.8 ±0.1 0.8 ± 0.2 0.9 ± 0.2 0.9 ± 0.2
Minute 0 0.8 ±0.2 0.9 ± 0.3 0.90.2 0.9 ± 0.2
Minute 10 1.3 ±0.3 b 1.1 ± 0.3 3.0 ± 1.4 a,* 3.0 *1.2b,#
Minute 20 1.1±0.4 1.0 ± 0.2 3.2 ± 1.6 b'* 3.5 ± 1.7b,#
Minute 30 1.2 ± 0.3 1.0 ± 0.2 3.5* 2.1 b'* 3.5 ± 1.4 "
Values are means ± SD. § Significantly different from below lactate threshold, P < 0.01; * significantly different
from NAL below lactate threshold, P < 0.01;11 significantly different from PLC below lactate threshold, P < 0.01;
a significantly different from Minute 0, P < 0.05; b significantly different from Minute 0, P < 0.01. NAL, naloxone
trial; PLC, placebo trial.
Plasma catecholamine concentrations
Plasma concentrations of NE over time for NAL and PLC trials in BLT (A) and
ALT (B) are presented in Figure 2. Neither control nor baseline plasma NE
concentrations were significantly different between groups for either NAL or PLC trial.
Plasma NE concentrations, significantly increased from baseline throughout exercise in
both groups and significantly greater in ALT than in BLT at minute 20 and 30 during


























Fig. 2 Plasma norepinephrine concentrations over time during exercise below
(A) and above (B) lactate threshold for naloxone and placebo trials. Values are
means ± SD; N=10. *Significantly different from NAL below lactate threshold, P
< 0.01;significantly different from PLC below lactate threshold, P < 0.05;
bsignificantly different from minute 0, P < 0.01. NAL, naloxone trial; PLC,
placebo trial46
ALT (Fig. 2B) but to be maintained in BLT (Fig. 2A) throughout exercise. In ALT,
plasma NE concentrations were significantly greater at minute 30 than at minute 10 in
the NAL trial but not in the PLC trial (Fig. 2B). Plasma NE was not significantly
different between the NAL and PLC trials during exercise regardless of intensities (Fig.
2), so that the administration of NAL did not significantly change plasma NE levels in
either BLT or ALT.
Plasma concentrations of Epi over time for NAL and PLC trials in BLT (A) and
ALT (B) are illustratedin Figure 3. Neither control nor baseline plasma Epi
concentrations were significantly different between groups for either NAL or PLC trial.
Plasma Epi concentrations tended to progressively increase throughout exercise for
both trials in ALT (Fig. 3B), but only the PLC trial showed a significant elevation from
baseline during exercise. Plasma Epi concentrations in BLT were unchanged from
baseline at any measurement time point and showeda similar pattern in each trial (Fig.
3A). There was no significant difference between the twogroups for either NAL or
PLC trial. Similarly to plasma NE, plasma Epi was not significantly different between
the NAL and PLC trials during exercise regardless of intensities (Fig. 3). Therefore,
neither the administration of NAL nor the two different intensities of exercise
significantly impact plasma Epi concentrations during exercise.
Plasma substrate concentrations
Figure 4 illustrates plasma concentrations of glycerol over time for NAL and PLC
trials in BLT (A) and ALT (B). No significant differences were found either between
groups or between trials at any time point, indicating that neither the intensities of
exercise nor the administration of NAL significantly influenced plasma glycerol
concentrations. The pattern of changes in plasma glycerol concentrations was similar
for each trial in each group. Plasma glycerol concentrations tended to be elevated from






























Fig. 3 Plasma epinephrine concentrations over time during exercise below (A)
and above (B) lactate threshold for naloxone and placebo trials. Values are
means ± SD; N=10. 'Significantlydifferent from minute0, P < 0.05;



















Fig. 4 Plasma glycerol concentrations over time during exercise below (A) and
above (B) lactate threshold for naloxone and placebo trials. Values are means ±


























Fig. 5 - Plasma free fatty acid concentrations over time during exercise below (A)
and above (B) lactate threshold for naloxone and placebo trials. Values are
means ± SD; N=10. NAL, naloxone trial; PLC, placebo trial50
minute 30 for both NAL and PLC trials in BLT (Fig. 4A) and only for the PLC trial in
ALT (Fig. 4B).
Figure 5 depicts plasma concentrations of FFA over time for NAL and PLC trials in
BLT (A) and ALT (B). No significant differences were found between groups or
between trials at any time point, indicating that neither the intensities of exercise nor
the administration of NAL affected plasma FFA concentrations. Plasma FFA
concentrations tended to decline from baseline at minute 10 of exercise in both groups,
and then elevate above baseline in BLT (Fig. 5A), but remained below baseline in ALT
(Fig. 5B).
Substrate oxidation rates
Figure 6 illustrates respiratory exchange ratios over time for NAL and PLC trials in
BLT (A) and ALT (B). Respiratory exchange ratios tended to be elevated from baseline
throughout exercise in both goups and more prominently in ALT, but only the PLC
trial in ALT exhibited significant increases from baseline during exercise (Fig. 6B). No
significant alterations were found between groups or between trials at any time point.
Rates of fatty acid and CHO oxidation were significantly increased from baseline
during exercise within each trial in each group (Figs. 7 and 8). No significant differences
in fatty acid oxidation were observed between groups at any time point for either NAL
or PLC trial (Fig. 7), whereas CHO oxidation was significantly greaterfor both trials in
ALT than in BLT throughout exercise (Fig. 8). No significant differences in fatty acid
and CHO oxidation were found between trials at any time point during exercise
regardless of intensities.
Figure 9 illustrates rates of total energy expenditure and energy expenditure derived
from CHO and fat at minute 20 of exercise. Rates of total energy expenditure and
energy expenditure from CHO were significantly greater foreach trial in ALT than in
BLT, whereas rates of energy expenditure from fat were similar for each trial in each
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Fig. 6 Respiratory exchange ratios over time during exercise below (A) and above
(B) lactate threshold for naloxone and placebo trials. Values are means ± SD;
N=10. l'Significantly different from minute 0, P < 0.01. NAL, naloxone trial;
























Fig. 7 Fatty acid oxidation over time during exercise below (A) and above (B)
lactate threshold for naloxone and placebo trials. Values are means ± SD; N=10.
bSignificantly different from minute 0, P < 0.01. NAL, naloxone trial; PLC,
















Pretest 0 10 20 30
Time (minutes)
Fig. 8 Carbohydrate oxidation over time during exercise below (A) and above (B)
lactate threshold for naloxone and placebo trials. Values are means ± SD; N=10.
ISignificantlydifferent from NAL belowlactatethreshold,P <0.05;
*significantlydifferentfrom NAL belowlactatethreshold,P <0.01;
significantlydifferentfrom PLC belowlactatethreshold,P <0.05;
msignificantlydifferentfrom PLC belowlactatethreshold,P <0.01;
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Fig. 9 Total energy expenditure and energy expenditure from carbohydrate and
fat at minute 20 of exercise below (A) and above (B) lactate threshold for
naloxone and placebo trials. Values are means ± SD; N=10. *Significantly
different from NAL below lactate threshold, P < 0.01; #significantly different
from PLC below lactate threshold, P < 0.01; :significantly different from CHO
oxidation, P < 0.01. CHO, carbohydrate; NAL, naloxone trial; PLC, placebo trial55
CHO and fat within each trial in ALT (Fig. 9B) but not in BLT, indicating that the
higher rates of energy expenditure from CHO contributed to the higher rates of total
energy expenditure in ALT. No significant differences in energy expenditure rates were
found between trials.
Discussion
The present study investigated the effects of a mu-opioid receptor antagonist, NAL,
on plasma concentrations of catecholamines (i.e., NE and Epi), glycerol (as an index of
lipolysis), and FFA and on fatty acid and CHO oxidation (indirect calorimetry) during
exercise at an intensity above or below LT in trained males. We observed that NAL did
not significantly alter plasma levels of catecholamines during exercise at an intensity
either above or below LT. NAL also did not significantly influence plasma levels of
glycerol or FFA or substrate oxidation during exercise at an intensity either above or
below LT.
It has been shown that plasma opioid peptides (e.g., B-EP) are abruptly increased
during exercise at LT (De Meirleir et al. 1986; Donevan and Andrew 1987; McMurray
et al. 1987; Rahkila et al. 1988; Taylor et al. 1994) and have an inhibitory role for
catecholamine secretion (Angelopoulos et al. 1995; Farrell et al. 1986; Grossman et al.
1984). A significant increase in plasma B-EP occurs concomitantly with increases in
plasma catecholamines during exercise above LT (McMurray et al. 1987; Schwarz and
Kindermann 1990). It was hypothesized that NAL would further augment exercise-
induced increases in plasma catecholamines during exercise above LT. Previous studies
have reported that the administration of NAL augmented exercise-induced increases in
plasma concentrations of catecholamines at a high exercise intensity (80% VO2max)
(Angelopoulos et al. 1995; Grossman et al. 1984), but not during low-intensity exercise
(40% VO2max) (Grossman et al. 1984). In the present study, plasma NE levels tendedto elevate incrementally during the duration of exercise above LT and were significantly
higher above LT than below LT (Fig. 2). By comparison, plasma NE levelswere rather
steady during exercise below LT. Table 2 shows that blood lactate concentrations were
significantly higher during exercise above LT than below LT. These data indicate that
an augmented increase in plasma NE secretion during exercise above LT would be
associated with lactic acidosis (i.e., LT), which is in agreement with previous findings
(Chwalbinska-Moneta et al. 1996; Mazzeo and Marshall 1989; Turner et al. 1995;
Weltman et al. 1994). However, NAL administration did not significantly affect plasma
catecholamine levelsduring exercise above LT,despitea trendthatplasma
catecholamine levels were slightly higher following NAL as compared with PLC (Figs.
2B and 3B).
Goldfarb et al. (1991) have shown that plasma levels of an endogenous opioid, B-
EP, were significantly elevated from resting values during 30 minutes of exercise at 70%
and 80%, but not at 60%, VO2max. Also, Angelopoulos et al. (1995, 1997) have
suggested that the endogenous opioid system is fully employed during prolonged
exercise at intensities higher than 75% of VO2max. The workloads at which the subjects
in ALT exercised in the present study averaged 68% and 70% of VO2peak for the NAL
and PLC trials, respectively (Table 2). Since plasma levels of endogenous opioid (e.g.,
B-EP) were not measured in the present study,itis unknown to what extent the
endogenous opioid system was actually activated during exercise at those intensities in
ALT.
Also, there were large ranges of individual workloads expressed as percent of
VO2peak (54 - 81% and 56- 80% for NAL and PLC trials, respectively), so that
considerable variances in workloads were observed withineach trial,although
workloads (V02) relative to LT were identical among subjects. It is likely that this
variation resulted in the failure to detect a significant effect of NAL on plasma
catecholamines in the present study. Plasma responses of catecholamines to exercise
are identical at relatively similar intensities regardless of training status (Kjaer 1992)57
and exercise mode (Hooker et al. 1990). In the present study, plasma NE and Epi levels
significantly correlated with % VO2peak (r = 0.656, P < 0.001 andr = 0.363, P < 0.05
for NE and Epi, respectively). Also, considerable variances in plasma NE (6.5- 22.5
TIM and 5.5 - 23.6 nM at minute 30 for NAL and PLC, respectively) and Epi (0.9- 3.5
nM and 0.8- 2.6 nM at minute 30 for NAL and PLC, respectively) were observed
during exercise above LT among the subjects within each trial, resulting in thevery low
power to detect statistically significant differences (see Appendix E).
Furthermore, it appears that the dose size of NAL influences plasmaresponses of
catecholamines to exercise (Bramnert and Hokfelt 1985; Grossman et al. 1984; Lam et
al. 1986; Staessen et al. 1985, 1986). In the present study,a 1.2 mg dose of NAL was
injected before exercise, based upon previous studies in which thesame dose size of
NAL enhanced exercise-induced increases in plasma NE (Angelopoulos et al. 1995) and
Epi (Angelopoulos et al. 1995; Farrell et al. 1991). On the other hand, Grossman et al.
(1984) employed a 12.2 mg dose (8 mg before exercise followed byan infusion of 5.6
mg11-1 during exercise), and observed augmented increases in plasma catecholamines.
Also, a dose of 8 mg of NAL caused augmented responses of plasma Epi to isometric
handgrip exercise (Lam et al. 1986). Staessen et al. (1985) have suggested thatas
exercise advances, NAL no longer reaches the opioid receptors in a sufficient amount to
sustain the antagonistic effect on the opioid inhibition in plasma catecholamine
secretion. However, the duration of action of small doses (0.4- 0.8 mg) is normally 1 to
4 hours, and its half-life in plasma is about 1 hour in resting humans (Jaffe and Martin
1990). In the present study, a bolus dose (1.2 mg) of NAL was injected 15 minutes
before the exercise test, and the duration of exercise was 30 minutes. It is unclear
whether the reason that NAL did notsignificantlyaffectplasmalevelsof
catecholamines in the present study is due to an insufficient dose size of NAL or
whether the B-EP levels were too similar at the two exercise intensities.
Shifts in energy substrate mobilization and utilization occur in association with
the LT (Brooks and Mercier 1994; Kanaley et al. 1995). Thus, to examine the effect ofNAL on plasma substrates and oxidation during exercise, intensities above and below
LT were chosen in this study. Toour knowledge, no previous study has investigated
the effects of NAL on plasma levels of glycerol and FFA andon fatty acid and CHO
oxidation in relation to exercise intensities above and below LT in humans. Itwas
hypothesized that an inhibition on B-EP effects would leadto an elevation in plasma
catecholamines, which would, in turn, lead toa reduction in FFA mobilization into the
circulation, possibly due to an inhibitory adrenergic mechanism during exercise above
LT.
In the present study, plasma levels of glycerol and FFA during exercisewere
identical between above and below LT (Figs. 4 and 5), despite significantly higher
levels of plasma NE above LT than below LT. These observationsare in accordance
with the findings of Kanaley et al. (1995), who reported similarpatterns of changes in
plasma glycerol and FFA between exercise intensities above and below LT. Also,
Romijn et al. (1993) have demonstrated that, although plasma levels of catecholamines
were significantly higher during exercise at 65% VO2max than at 25% V02.,1, plasma
levels of FFA were similar between the two intensities.
FFA mobilization (rate of FFA appearance) has been shown to be significantly
reduced possibly due to a-adrenergic inhibition during high-intensity exerciseas
compared to during lower-intensity exercise (Kanaley et al. 1995; Romijn et al. 1993).
Rate of FFA appearance was not examined in the present study. However, fatty acid
oxidation was found to be identical at the intensities above and below LT. Plasma
glycerol levels during exercise were also similar between above and below LT. The
underlying mechanism(s) of those responses are unclear. The workloads at which the
subjects exercised averaged 69% and 54% VO2peak in ALT and BLT, respectively. The
difference in % VO2peak between the two groups (i.e., 15%) might have been too small
to detect the intensity effect on plasma levels of glycerol and FFA in the present
study.59
NAL administration also did not significantly influence plasma levels of glycerolor
FFA, or fatty acid or CHO oxidation during exercise atan intensity either above or
below LT in the present study. It was observed that, during exercise above LT, fatty
acid and CHO oxidation tended to be lower and higher, respectively, following NALas
compared to PLC (Figs. 7B and 8B). Farrell et al. (1986) employedan oral dose of
naltrexone (50 mg), another mu-opioid receptor antagonist, to examine the effectson
plasma catecholamines, serum FFA and RQ duringa 30-minute bicycle exercise at 70%
of V02. in humans. They found that, althoughan exercise-induced increase in plasma
Epi was significantly augmented by naltrexoneas compared to the placebo trial, serum
levels of FFA and the RQ were not significantly altered. However, in rats whichwere
forced to swim for 60 minutes, NAL injection before the start of exercise significantly
reduced exercise-induced increases in plasma glycerol and FFA (Vettor et al. 1987).
Also,it has been reported that NAL significantly reduced the exercise-induced
elevation in plasma glucagon during prolonged exercise at 80% of VO2max in humans
(Angelopoulos et al.1997). Further investigation is required to clarify whether
endogenous opioids are involved in fat mobilization and substrate oxidation during
exercise at higher intensities (i.e., > 75% V02.0 in humans.
CHO oxidation was significantly greater during exercise above LT than below LT
(Fig. 8). This is in agreement with previous findings that demonstrated higher CHO
oxidation, without a change in fatty acid oxidation, during high-intensity exercise as
compared to low-intensity exercise (Kanaley et al. 1995; Kang et al.1999). It is
possible that the enhanced levels of plasma NE during exercise above LT facilitated
muscle glycogenolysis (Brooks and Mercier 1994), resulting in elevated blood lactate
levels. The enhanced energy production from CHO contributed to the increased total
energy expenditure during exercise above LT (Fig. 9). Also, CHO was the primary
substrate for oxidation during exercise above LT, since energy production from CHO
significantly exceeded that from fat. These findings support the "crossover" concept of
Brooks and Mercier (1994).60
In summary, theadministrationof endogenous opioidantagonistdid not
significantly alter plasma levels of catecholamines, glycerol and FFA during exercise
either 10% above or 10% below LT. Also, substrate oxidation was not significantly
influenced by the opioid antagonist during exercise. Therefore, during exercise atan
intensity 10% above or 10% below LT, endogenous opioids may not play regulatory
rolesincatecholaminesecretionandsubstratemetabolism.However,further
investigations are required to reexamine the effects of opioid antagonist by employing
higher intensities of exercise (i.e., > 75% V02.,) and/or a higher dose of opioid
antagonist (i.e., > 1.2 mg). Plasma levels of glycerol and FFA and fatty acid oxidation
were not altered regardless of the intensities, whereas CHO oxidation was significantly
greater above LT than below LT. Enhanced carbohydrate oxidation contributed to
elevated energy demands during exercise above LT.
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The effect of opioid receptor antagonismon plasma catecholamines and fat
metabolism during prolonged exercise belowor above lactate threshold in males
Investigators: Anthony Wilcox, Ph. D. and Hirotaka Hikoi, M. E.
Department of Exercise and Sport Science, Oregon State University
Purpose: The purpose of the present study is to study the effect ofan endorphin-
blocking drug on metabolism and hormone release during exercise. Endorphinsare
opioid substances that the body produces during exercise, and theyare believed to
produce pleasant feelings and have pain-reducing effects. There is evidence that
endorphins influence exercise metabolism (fat and carbohydrate utilization) through
their effects on catecholamine levels (epinephrine and norepinephrine-- also known as
adrenaline and noradrenaline). This study will evaluate this effect at two exercise
intensities, using a drug, naloxone, which blocks the effects of endorphins.
I have received an oral explanation of the study procedures and understand they
entail:
1. Preliminary test for peak oxygen uptake (V02 peak) and lactate threshold
I will report to the laboratory at least 3 hours after breakfast having refrained
from strenuous physical activity for the previous 24 hours. I will then be fitted
with chest electrodes to monitor my heart rate. I willwarm up and then
undergo a test of my aerobic capacity on a bicycle ergometer. With the initial
workload set at 100 watts, workloads will be increased by 25 wattsevery 3
minutes, until I obviously exceed my lactate threshold (LT) basedon the
readings of blood lactate (an acid byproduct of high intensityexercise
metabolism) concentration, and then every 1 minute until I become too fatigued
to continue or request to end the test. Each test will take approximately 20 to
30 min. During the tests, I will breathe room air through a mouthpiece so that
the amount of oxygen my body is using can be determined. Finger-stick blood
samples will be taken at rest and at 3-minute intervals during the test to
analyze blood lactate concentration for the determination ofmy LT (the
exercise intensity at which my blood lactate levels begin to increase).80
2. Experimental tests for blood and plasma measurement
At least 7 days after completing the peak exercise test, I will report to the
laboratory to perform two submaximal exercise testson a bicycle ergometer,
once with an intravenous infusion of 1.2 mg naloxone (NAL), the other time
with an infusion of a saline placebo (PLC). I will arrive at the lab followingan
overnight fast, and I will refrain from taking any medications, nicotine, caffeine,
or alcohol for 48 hours prior to the exercise sessions. Each exercise session will
be separated by at least 7 days. I will be randomly assigned to cyclemy two
exercise sessions at a constant work rate corresponding to either 10% belowor
10% above my LT (not both). I will cycle for 30 minutesor as long as I can if I
cannot complete 30 minutes. Prior to the exercise tests, I will have a catheter (a
thin flexible Teflon tube) inserted into a forearm vein bya physician, for the
removal of blood samples during the exercise.
Twenty (20) minutes before the exercise tests, I will be-infused with a 1.2 mg
dose of NAL or PLC through the catheter byan attending physician.
A 10 ml blood sample will be drawn through the catheter 10 minutes before, at
the start of, and every 10 minutes during the exercise tests, and again 10
minutes after the exercise, for the measurement of blood lactate, hematocrit
(Hct), and hemoglobin (Hb) and plasma norepinephrine, epinephrine, free fatty
acids, and glycerol. The six 10 ml samples total 60 ml of blood being withdrawn
in the exercise session, which is equivalent to 4 tablespoons in volume.
During the test, I will breathe througha mouthpiece so that my oxygen
consumption can be measured. Heart rate will be continuously monitored
electrocardiographically.
3. Body composition test using hydrostatic weighing
Before the preliminary exercise test,my body composition (percent body fat)
will be assessed using an underwater weighing procedure ina specially
designed indoor tank. Water in the tank will be near body temperature (35-37
°C). I will sit on a chair that is suspended from a scale and submerge myself
following a maximal exhalation and remain underwater for 2 to 3sec while the
scale is read. This procedure is repeated 5 to 6 times. I will also performa test
to determine my residual lung volume (volume of air in the lungs following a
maximal exhalation). Two or three such trials will be performed.
4. Risks
I understand that the peak exercise test presents a remote risk of death or a
cardiac event such as abnormal heart rhythms. However, in large, varied
populations, the risk of death is one per 10,000 tests. Since I am healthy and
physically well-trained and will be screened to exclude individuals with known81
symptoms of heart disease, the risk is much less. Also, the tests will be
administered by trained personnel, certified in cardiopulmonary resuscitation
(CPR), who will monitor for signs of exercise intolerance. Furthermore, I am
aware that the exercise tests may present a small chance of muscle strain or
soreness. Since I will be instructed in appropriate warm-up and cool-down
procedures by the investigators, the chance of muscle strain or soreness will be
minimized.
Also, I understand that an intravenous infusion of 1.2 mg of NAL will not be
harmful for my health, since subcutaneous doses of NAL (up to 12 mg) do not
produce recognizable subjective effects, and NAL neither produces tolerance or
physical and psychological dependence, nor does it induce pharmacological
activity in the absence of narcotics. Furthermore, administrating NAL to me
will be innocuous since I am not physically dependent on opioids, I am not
postoperative, and I have no known cardiac abnormalities. Additionally, a
physician will be administering the dose.
6. Benefits
I will benefit from my participation by gaining information regarding my peak
exercise capacity (V02 peak and LT) and percent body fat. Such information
may be useful for me to make decisions related to my health habits and
lifestyle.
I understand that participation in this study will entail 4 laboratory sessions, each
requiring 45 to 60 minutes, over a 3-week period. The first session will be for
determination of my body composition (percent body fat). The second session will be
for determination of my exercise capacity. The last two sessions will be to investigate
the effect of NAL (and PLC) on plasma hormones and substrates andon fat
metabolism during exercise below or above LT.
Any information obtained from me will be kept confidential. A code number will be
used to identify any test results or other information that I provide. The only persons
who will have access to this information will be the investigators, andno names will be
used in any data summaries or publications.
I understand that the Universitydoes not provide a researchsubjectwith
compensation or medical treatment in the event that the subject is injured as a result of
participation in the research project.
Questions about this research or any aspects of my participation in it should be
directedtoAnthonyWilcox,DepartmentofEXSS(737-2643or
wilcoxa@ccmail.orst. edu) or Hirotaka Hikoi (753-9646 or hikoih@ucs.orst.edu). Any82
other questions that I have should be directed. to Mary Nunn, Sponsored Programs
Officer, OSU Research Office, 737-0670).
I have been completely informed and understand the nature andpurpose of the
research project. The researchers have offered toanswer any further questions that I
may have. I understand that my participation in this study is completely voluntary
and I may withdraw from the study at any time without penaltyor loss of benefits to
which I am otherwise entitled.









Age Gender Height Weight
Circle the appropriate responses:
1. Do you currently smoke cigarettes or cigars?
yesno
Have you smoked regularly within the last 5 years?
yesno
2. Have you been diagnosed as having cardiac abnormalities?
yesno
3. Have you been diagnosed as having high blood pressure?
yesno
Have you ever been treated for "sugar diabetes" (diabetes mellitus)?
neverwith pills with insulin injections
5. Did either of your parents or a sibling havea "heart attack" or bypass surgery?
do not knowneither one both
If so, were they :under age 5555 years or over
6. Have you ever had an elevated blood cholesterol level (over 200 mg/dl)?
do not knownoyes
Do you know your blood cholesterol level? mg/dl7. Do you have infectious mononucleosis?
yesno
8. Are you taking any narcotics?
yesno
9. Have you taken any hormone therapy in last 6 months?
yesno
10.Have you had any history of endocrine disorders within the last 6 months?
yesno
11.Have you been operated on within the last 6 months?
yesno
12.List any prescription medications you are taking and give amounts.
13.Describe your exercise habits in the past year.Appendix B
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Warren N. Suzuki, ChairJ




Determination of Plasma Catecholamine Concentrations
The determination of plasma catecholamine concentrations (NE and Epi) was
performedusinghigh-performanceliquidchromatography(HPLC)with
electrochemical detection by a procedure modified from Weltman et al. (1994).
The plasma sample (1.0 ml) was thawed, vortexed and adsorbed to 25 mg of acid-
washed alumina (Bioanalytical Systems) in a plastic conical tube, containing solutions:
50 gl of 5 mM sodium metabisulfite (NaMBS) (Sigma Chemical), 200 gl of 10 ng-m1-1
3,4-dihydroxy-benzylamine hydrobromide (DHBA) (DHBAHBr, Sigma Chemical)
served as an internal standard, and 400 gl of 1 M tris (hydroxymethyl) aminomethane
(Sigma Chemical) containing 2g% EDTA (1. M tris-2 g% EDTA) (Sigma Chemical)
adjusted to pH 8.6 with hydrochloric acid. Also, a blank tube without plasma and
DHBA was prepared to detect contamination of reagents.
After inversely mixing the samples for 20 minutes using a tube rotator, the alumina
was sedimented by microcentrifugation at 3000 rpm for one minute, and the
supernatant was discarded. The alumina was then washed three times with distilled
water and microcentrifuged at 3000 rpm for 1 minute each time after washed to remove
excess water. 200 Ill of 0.1M perchloric acid (Fisher) was added to the alumina to
desorb catecholamines and vortexed for 30 seconds. The tube was then centrifuged at
3000 rpm for 1 minute and allowed to stand for 15 minutes. The eluate was filtered
using a 0.2-gm pore size filter into HPLC sample vials with 200 gl-capacity
polypropylene inserts (National Scientific). 75 gl of the eluate of blank and plasma
samples was autoinjected into a HPLC column for the measurements. Five of plasma
samples were assayed in duplicate each analysis.87
Alumina was stored in a dessicator.1 M tris-2 g% EDTA was stored in a
refrigerator and readjusted to pH 8.6 with hydrochloric acid when analyzed. 10 ngm1-1
of DHBA dilution was prepared with 0.1 M perchloric acid from the stock standard
when analyzed and stored in a refrigerator. NaMBS was stored in a refrigerator. 25 mg
of alumina should be enough to absorb catecholamines if the alumina is thoroughly
mixed with plasma at an appropriate pH, since the concentrations in plasma are very
low (Goldstein, 1986).
The HPLC system consisted of a solvent delivery module (LC-10AD, Shimadzu),
autoinjector(SIL-10A,Shimadzu),systemcontroller(SCL-10,Shimadzu),
electrochemical detector (L-ECD 6A, Shimadzu) using a glassy carbon working
electrode with an applied potential of +720 mV with 0.5 nA-volt-1. The mobile phase
consisted of 1000 ml of a solution: 13.799 g sodium dihydrogen phosphate (Fisher),
0.372 g EDTA, 0.197 g octyl sulfate sodium salt (Sigma Chemical), and 100 ml of
methanol. The mobile phase was adjusted to pH 3.0 with hydrochloric acid. The
mobile phase was prepared and degassed each night before analysis the following
morning. 0.2 -pm filtered distilled water was used for all dilutions and reagents. The
solvent flow rate was set at 1.0ml.min-1. A 5-p.m C18 150 x 4.6 mm column and 30 x
4.6 mm guard column (Luna, Phenomenex), and HPLC column water jacket (Supelco)
were used and maintained around 40 °C. Peak heights were quantified using a
Chromatopac integrator (CR501, Shimadzu) set at width of 2.5, slope of 250,
minimum area of 100, attenuation of 3, speed of 3, and stop time of 15 minutes.
Catecholamine standards, norepinephrine bitartrate salt (NE-HC1, Sigma Chemical)
and epinephrine bitartrate salt (Epi), and an internal standard (DHBA) were used in
the analysis. 10 ggin1-1 of each standard was prepared with 0.1 M perchloric acid and
stored in 1.5 ml plastic tubes at -80 °C until analysis. 10 ngm1-1 of the dilution
containing each stock standard was prepared with 0.1 M perchloric acid when analyzed
and stored in a refrigerator. 75 pl of the standard dilution was autoinjected into a HPLC
column for the standard measurements.88
The percent recovery was calculated from the ratio of DHBA peak heights between
standard and plasma sample injections. The recovery from the alumina extraction
averaged 78%. The ratios of the NE and Epi peak heights froma plasma sample
injection divided by the recovery to those from standard injectionwas used to calculate
catecholamine concentrations. Plasma catecholamine concentrations were expressed in
nM. The limit of detectability for both NE and Epi were 0.6 and 0.5 nM, respectively.
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1149.TABLE 1. Subject characteristics.
BLT
AgeHeightWeight%body fatVO2peakVO2peak/kgHRpeakLapeakWoridoadgLTV02@LT%VO2 @LTAssign. workload
#1 24 16364.0 12.3 4.0 63.0 189 13.1 201 40.0 63.6 180
#3 29 18076.0 8.4 4.3 57.0 192 10.6 125 33.8 59.4 110
#4 26 178 77.0 8.4 5.4 70.1 182 11.6 272 46.5 66.3 230
#9 18 18368.0 4.2 4.9 71.7 208 6.9 226 45.7 63.7 200
#10 22 170 72.5 10.3 4.6 63.4 184 7.9 203 39.8 62.7 180
#12 23 191 82.0 12.6 5.1 62.6 192 10.6 231 36.6 58.4 190
#16 31 170 79.0 13.6 3.8 47.9 182 9.4 163 32.8 68.4 140
#18 21 189 80.5 5.4 5.8 71.6 195 10.7 212 39.0 54.4 190
#19 35 18481.0 17.3 4.5 55.3 162 9.1 202 38.1 68.9 180
#20 28 175 82.5 26.3 5.3 64.7 191 8.4 223 44.6 68.9 200
Mean25.7178.3 76.2 11.8 4.7 62.7 187.7 9.8 205 39.6 63.4 180
SD 5.1 8.9 6.2 6.3 0.6 7.6 11.8 1.9 39 4.7 4.9 33
ALT
AgeHeightWeight%body fatVO2peakVO2peak/kgHRpeakLapeakWorkload@LT,V02@LTVoVOZOLTAssign. workload
#2 23 180 70.0 9.7 4.8 68.2 201 11.1 169 45.0 66.0 190
#5 26 18972.0 13.0 4.3 59.8 183 10.3 234 41.3 69.1 260
#6 26 17870.0 10.0 4.7 67.4 189 13.0 219 41.1 61.0 250
#7 23 185 86.0 11.5 4.9 56.6 199 7.3 198 36.0 63.7 220
#8 22 17968.0 8.9 4.2 61.2 199 12.9 213 42.6 69.5 240
#11 18 170 62.5 19.0 4.1 65.6 206 11.4 149 37.7 57.4 178
#13 19 171 72.0 15.4 4.8 66.2 191 10.0 199 44.0 66.5 220
#14 27 173181.5 16.0 4.9 60.0 188 8.1 218 35.8 59.7 240
#15 19 18077.0 11.6 5.1 66.1 192 10.7 234 40.7 61.6 270
#17 22 190 80.0 3.7 4.5 56.5 185 12.7 185 34.6 61.3 213
Mean22.5179.473.9 11.8 4.6 62.7 193.3 10.7 201 39.8 63.5 228
SD 3.1 6.9 7.0 4.2 0.3 4.4 7.6 1.9 27 3.6 4.0 29TABLE 2. Heart rate (beats/min).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 45 74 55 65 68 73 54 67 63 74 63.8 9.7
Min 0 44 73 55 60 65 75 54 63 61 82 63.2 11.2
Min 10 128 134 138 145 129 126 118 128 115 156 131.7 12.2
Min 20 124 133 139 141 136 126 119 130 113 156 131.7 12.3
Min 30 123 134 140 152 138 130 119 132 115 159 134.2 13.9
PLC
Control (-10) 45 71 62 73 70 77 60 82 56 67 66.3 10.9
Min 0 43 61 63 70 71 73 58 79 58 73 64.9 10.5
Min 10 121 115 131 160 132 129 119 151 -108 154 132.0 17.6
Min 20 125 117 130 163 128 131 126 160 109 154 134.3 18.4
Min 30 126 117 133 166 130 133 132 164 110 156 136.7 19.1
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10) 85 70 74 74 77 76 70 72 66 73 73.7 5.1
Min 0 84 69 58 73 74 75 70 69 69 80 72.1 7.1
Min 10 173 165 145 156 160 167 159 141 152 166 158.4 10.1
Min 20 177 168 146 163 167 171 170 142 152 170 162.6 11.8
Min 30 181 172 149 173 173 172 182 147 153 169 167.1 12.8
PLC
Control (-10) 70 68 66 85 71 74 78 59 66 80 71.7 7.7
Min 0 73 69 56 82 71 74 78 58 67 78 70.6 8.5
Min 10 166 169 145 162 165 170 157 136 156 165 159.1 11.0
Min 20 171 177 150 168 165 172 166 141 158 169 163.7 11.0
Min 30 181 173 155 168 173 175 174 139 159 171 166.8 12.4TABLE 3. Oxygen consumption (Umin).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 0.2 0.3 0.4 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.0
Min 0 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.0
Min 10 2.3 1.9 3.1 2.6 2.5 2.5 2.2 2.5 2.6 3.1 2.5 OA Min 20 2.4 1.9 3.2 2.6 2.5 2.5 2.2 2.6 2.6 3.1 2.6 0.4
Min 30 2.4 1.9 3.2 2.6 2.5 2.5 2.2 2.7 2.6 3.2 2.6 0.4
PLC
Control (-10) 0.2 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.3 0.3 0.3 0.1
Min 0 0.1 0.4 0.3 OA 0.3 0.3 0.4 0.4 0.3 0.4 0.3 0.1
Min 10 2.3 1.7 3.2 3.0 2.6 2.7 2.2 2.4 2.5 2.7 2.5 0.4
Min 20 2.4 1.7 3.1 2.9 2.7 2.7 2.3 2.7 2.5 2.9 2.6 0.4 Min 30 2.3 1.7 3.2 2.9 2.7 2.7 2.3 2.8 2.5 2.9 2.6 0.4
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10) 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.4 0.3 0.0
MM 0 0.3 0.3 0.3 0.4 0.3 0.2 0.3 0.4 0.4 0.3 0.3 0.0
Min 10 3.0 3.3 3.2 3.4 3.1 2.3 3.0 3.2 3.8 2.7 3.1 0.4
Min 20 2.9 3.5 3.3 3.4 3.1 2.4 3.1 3.1 3.8 2.9 3.2 0.4
Min 30 2.9 3.5 3.2 3.5 3.1 2.4 3.6 3.3 3.8 3.1 3.2 0.4
PLC
Control (-10) 0.3 0.3 0.3 0.2 0.3 0.4 0.3 0.4 0.4 0.4 0.3 0.1
Min 0 0.3 0.3 0.4 0.2 0.3 0.3 0.3 0.3 0.5 0.4 0.3 0.1
Min 10 2.9 3.3 3.3 3.6 3.2 2.4 3.1 3.3 3.7 3.0 3.2 0.4
Min 20 3.0 3.4 3.2 3.8 3.2 2.4 3.2 3.3 3.8 3.2 3.2 0.4
Min 30 3.3 3.3 3.4 3.7 3.1 2.4 3.3 3.3 3.8 3.2 3.3 0.4TABLE 4. Oxygen consumption (ml/k: min).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 3.7 3.8 5.0 4.8 3.8 3.8 3.9 4.7 3.4 4.1 4.1 0.5
Min 0 3.9 3.9 4.1 4.5 3.9 4.2 3.3 3.7 3.7 4.4 4.0 0.4
Min 10 35.8 24.0 41.5 37.1 35.3 30.7 27.8 29.4 31.9 38.6 33.2 5.4
Min 20 36.8 24.7 42.9 37.8 34.7 31.1 28.5 30.9 31.8 38.8 33.8 5.4
Min 30 37.0 24.4 42.2 38.3 35.3 31.3 28.5 31.6 32.5 39.4 34.1 5.4
PLC
Control -10 2.8 3.7 4.0 5.0 5.3 4.2 4.0 5.2 3.8 4.1 4.2 0.8
Min 0 2.2 5.2 4.5 5.7 4.4 4.0 5.3 4.9 3.5 4.6 4.4 1.0
Min 10 36.5 21.2 42.4 43.2 35.0 33.3 28.2 28.8 31.0 33.6 33.3 6.6
Min 20 37.5 21.2 41.4 41.5 36.9 34.1 29.7 31.5 30.3 35.6 34.0 6.1
Min 30 36.5 21.4 42.1 41.6 36.9 33.9 30.3 32.4 30.5 35.5 34.1 6.0
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10) 4.1 3.6 4.8 4.0 3.9 4.3 4.6 4.5 3.9 4.7 4.2 0.4
Min 0 4.5 4.5 3.7 4.1 4.1 3.8 4.2 4.6 5.3 4.2 4.3 0.4
Min 10 42.6 46.5 45.0 39.2 45.1 35.1 42.5 41.3 49.7 34.1 42.1 4.9
Min 20 41.3 48.0 46.2 39.0 45.5 37.9 43.6 39.8 50.5 36.5 42.8 4.7
Min 30 41.6 48.5 45.3 40.8 44.6 37.2 50.2 42.0 50.4 38.2 43.9 4.7
PLC
Control (-10) 4.1 4.5 4.6 2.2 4.7 5.7 4.6 4.4 4.8 5.3 4.5 0.9
Min 0 4.9 3.7, 5.4 2.2 4.7 .5.1 4.4 4.2 6.1 5.1 4.6 1.1
Min 10 40.7 45.9 46.9 41.2 46.3 37.1 45.3 41.7 48.6 36.5 43.0 4.2
Min 20 43.4 47.6 45.6 43.6 45.7 36.8 47.0 41.5 49.1 38.8 43.9 3.9
Min 30 47.3 46.8 47.3 42.6 45.5 37.8 48.7 40.8 50.0 38.9 44.6 4.3TABLE 5. Percent of VO2 peak.
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 5,8 6.6 7.1 6.7 6.0 6.1 8.2 6.6 6.2 6.3 6.6 0.7
Min 0 6.2 6.9 5.9 6.2 6.1 6.7 6.8 5.2 6.6 6.9 6.3 0.5
Min 10 56.9 42.1 59.2 51.7 55.7 49.0 57.9 41.1 57.7 59.7 53.1 6.9
Min 20 58.5 43.3 61.2 52.7 54.8 49.7 59.6 43.2 57.4 60.0 54.1 6.7
Min 30 58.7 42.9 60.2 53.3 55.6 50.0 59.6 44.2 58.9 60.9 54.4 6.7
PLC
Control (10) 4.4 6.6 5.7 7.0 8.4 6.6 8.4 7.3 6.9 6.3 6.8
1'21 Min 0 3.5 9.1 6.4 7.9 6.9 6.3 11.2 6.8 6.4 7.2 7.2 2.0
Min 10 58.0 37.2 60.4 60.3 55.2 53.1 58.9 40.1 56.0 51.9 53.1 8.2 Min 20 59.6 37.2 59.1 57.8 58.2 54.5 62.0 44.0 54.8 55.0 54.2 7.7
Min 30 57.9 37.6 60.1 57.9 58.3 54.2 63.3 45.2 55.2 54.9 54.5 7.6
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10) 5.9 6.0 7.1 7.1 6.4 6.6 7.0 7.5 5.9 8.4 6.8 0.8
Min 0 6.5 7.5 5.5 7.3 6.7 5.8 6.3 7.7 7.9 7.4 6.9 0.8
Min 10 62.4 77.7 66.8 69.3 73.7 53.6 64.2 68.8 75.2 60.3 67.2 7.4
Min 20 60.5 80.2 68.6 69.0 74.3 57.8 65.8 66.4 76.4 64.7 68.4 7.0
Min 30 60.9 81.1 67.2 72.2 72.8 56.7 75.8 69.9 76.2 67.6 70.0 7.3
PLC
Control (10) 6.0 7.4 6.8 3.9 7.6 8.6 6.9 7.3 7.2 9.4 7.1 1.5
Min 0 7.2 6.3 8.0 3.8 7.6 7.8 6.7 6.9 9.3 9.0 7.3 1.5
Min 10 59.7 76.8 69.6 72.8 75.7 56.5 68.4 69.5 73.5 64.7 68.7 6.7
Min 20 63.6 79.7 67.7 77.1 74.6 56.2 70.9 69.1 74.2 68.7 70.2 6.9
Min 30 69.4 78.2 70.1 75.2 74.4 57.6 73.6 68.0 75.7 68.9 71.1 5.8TABLE 6. Blood lactate concentrations (mM).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 0.7 0.9 0.7 0.9
_
0.9 0.6 0.6 1.1 1.0 0.6 0.8 0.2
Min 0 0.8 1.0 0.7 1.0 1.2 0.6 0.5 1.0 0.9 0.6 0.8 0.2
Min 10 1.4 1.8 1.1 1.3 1.7 0.7 1.3 1.8 1.0 1.3 1.3 0.4
Min 20 1.1 1.9 1.0 0.9 1.4 0.7 1.6 1.6 0.8 0.8 1.2 0.4
Min 30 1.2 1.6 1.1 1.0 1.5 0.7 1.9 1.4 0.9 0.8 1.2 0.4
PLC
Control (-10) 0.9 0.9 0.6 0.8 0.8 0.7 0.7 0.9 1.2 1.2 0.9 0.2
Min 0 0.9 1.6 0.7 0.7 0.8 0.6 0.5 0.9 1.2 1.2 0.9 0.3
Min 10 1.0 1.2 0.9 1.2 0.7 0.9 1.7 1.2 1.4 1.7 1.2 0.3
Min 20 0.9 1.2 0.8 1.0 0.9 0.8 1.5 1.1 1.1 1.4 1.1 0.2
Min 30 0.9 1.2 0.9 1.0 1.0 0.8 1.8 1.1 1.1 1.2 1.1 0.3
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10) 0.8 1.0 1.0 1.1 0.8 1.4 1.2 0.8 1.0 0.7 1.0 0.2
Min 0 0.8 0.8 0.9 1.2 0.6 1.4 1.2 0.8 1.1 0.7 1.0 0.3
Min 10 2.3 4.2 2.8 2.6 2.7 1.7 3.5 2.1 2.3 6.5 3.1 1.4
Min 20 2.1 4.0 3.2 2.9 2.9 1.5 4.4 2.1 2.0 7.2 3.2 1.7
Min 30 1.9 4.2 3.0 4.1 3.1 1.4 7.4 1.9 2.1 7.1 3.6 2.1
PLC
Control (-10) 0.8 0.9 1.1 1.1 0.9 1.1 0.6 0.7 1.5 0.8 0.9 0.3
Min 0 0.8 0.9 1.3 0.9 0.8 1.1 0.6 0.7 1.4 0.7 0.9 0.3
Min 10 1.6 5.4 3.9 3.0 3.4 2.6 1.3 1.9 2.7 4.2 3.0 1.3
Min 20 2.0 6.3 3.6 3.6 4.6 2.5 1.7 2.0 2.8 6.6 3.6 1.8
Min 30 2.9 5.8 3.2 3.5 4.9 2.4 2.5 1.6 3.0 5.7 3.5 1.4TABLE 7. Percent of plasma volume changes.
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10)
Min 0 1.7 2.2 7.8 -2.2 1.8 -1.9 -4.0 -1.0 9.4 3.2 1.7 4.3
Min 10 0.9 0.6 0.9 -10.0 -6.9 -4.9 -8.6 -0.3 4.8 -3.8 -2.7 4.8
Min 20 3.7 -4.2 -3.9 -7.2 -5.8 -3.8 -7.4 3.6 1.3 -7.2 -3.1 4.4
Min 30 7.2 -6.2 -2.0 -12.5 -6.4 -4.7 -8.0 2.9 1.2 -3.6 -3.2 5.7
PLC
Control (-10)
Min 0 3.3 8.6 11.4 -2.6 0.6 8.6 -0.5 -3.7 0.7 1.4 2.8 5.1
Min 10 2.5 6.9 1.5 -6.4 -9.6 1.3 -8.2 -7.0 -5.4 -1.0 -2.5 5.5
Min 20 3.2 0.0 0.6 -9.9 -8.0 3.8 -6.5 -5.6 -5.4 2.7 -2.5 5.1
Min 30 7.2 31.5 2.6 -12.3 -9.1 7.5 -9.0 0.1 -1.8 2.7 1.9 12.5
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10)
Mint) 1.6 8.7 7.6 1.4 0.2 -6.3 -11.5 -0.1 1.7 -1.8 0.1 5.9
Min 10 -7.7 -4.9 19.2 4.2 -10.0 -3.0 -31.4 -3.0 -10.7 -13.9 -6.1 13.0
Min 20 -10.9 -1.9 6.1 16.3 -10.8 -6.3 -41.4 -4.4 -11.5 -14.4 -7.9 15.0
Min 30 -9.7 -3.1 3.7 -8.7 -10.2 -7.7 -34.0 -5.0 -11.5 -13.4 -10.0 9.8
PLC
Control (10)
Min 0 -2.4 1.3 -2.1 -4.4 0.0 -2.2 1.2 -2.1 3.6 1.8 -0.5 2.5
Min 10 -3.3 -11.8 -10.4 -10.7 -10.7 -7.4 -5.3 -5.3 -5.5 -5.8 -7.6 3.0
Min 20 -3.0 -13.8 -11.3 -12.7_ -12.4 -5.1 -4.4 -5.9 -5.4 -6.0 -8.0 4.1
Min 30 -5.1 -12.8 -13.7 -13.1 -10.2 -9.6 -5.2 -5.3 -5.0 -0.3 -8.0 4.5TABLE 8. Plasma norepinephrine concentrations (nM).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 2.39 3.27 3.38 3.93 3.07 2.91 3.84 2.06 2.93 1.69 2.95 0.73
Min 0 2.50 1.55 3.60 1.35 3.67 3.17 4.35 1.67 3.26 2.20 2.73 1.03
Min 10 7.17 3.28 9.54 4.43 8.07 4.20 4.61 3.10 7.64 7.21 5.92 2.25
Min 20 7.36 3.68 9.98 4.52 9.27 4.10 4.22 3.81 8.44 7.49 6.29 2.47
Min 30 7.53 2.87 10.58 4.01 5.19 5.34 4.74 4.39 8.97 9.73 6.34 2.67
PLC
Control (-101 2.91 3.01 4.75 1.79 1.92 2.92 2.46 3.06 2.82 1.41 2.70 0.92
Min 0 2.93 3.86 4.73 1.73 2.02 3.31 2.59 2.20 2.61 1.60 2.76 0.99
Min 10 6.54 4.02 9.87 5.98 6.02 4.12 5.10 4.75 6.22 6.51 5.91 1.68
Min 20 8.88 3.05 11.63 6.80 6.26 5.10 5.58 6.14 7.35 6.47 6.73 2.29
Min 30 9.84 4.28 13.09 7.31 3.55 5.57 5.76 8.48 8.54 6.55 7.30 2.83
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-101 4.21 1.80 4.24 2.51 2.40 1.86 2.02 3.31 2.05 3.18 2.76 0.93,
Min 0 2.91 2.42 4.58 2.41 2.13 1.56 1.93 3.19 2.05 2.77 2.59 0.85
Min 10 13.96 11.84 10.69 10.49 8.02 4.87 4.42 6.06 7.41 8.68 8.64 3.10
Min 20 17.20 17.59 11.73 12.89 11.55 6.43 10.79, 6.46, 9.10 13.50 11.72 3.84
Min 30 16.84 18.74 11.30 15.08 12.45 633 22.47 6.71 10.03 14.75 13.49 5.12
PLC
Control (-10) 4.79 3.40 3.21 2.11 2.01 2.22 2.43 3.15 1.66 2.60 2.76 0.91
Min 0 4.42 2.95_ 4.05 1.92 2.33 2.20 2.52 2.65. 2.69 2.76 0.86
Min 10 11.79 7.03 7.65 7.82 7.99 5.92 11.72 4.92 8.03 8.09 8.10 2.19
Min 20 15.96 9.51 8.99 8.29 9.74 8.34 17.42 5.98 9.64 15.63 10.95 3.90
Min 30 17.64 11.21 10.80 9.37 11.15 9.35 23.55_ 5.52r
10.45 15.06 12.41 5.10TABLE 9. Plasma epinephrine concentrations (nM).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 0.58 0.55 0.75 0.56 0.50 0.40 1.64 0.75 0.77 0.92 0.74 0.35 Min 0 0.71 0.37 1.20 0.82 0.73 0.38 1.30 0.86 1.06 0.97 0.84 0.31 Min 10 0.91 0.54 1.24 0.66 1.06 0.62 1.54 1.17 1.44 0.84 1.00 0.35 Min 20 0.82 0.94 0.94 1.00 0.92 0.61 2.06 1.07 0.84 1.12 1.03 0.39 Min 30 0.79 0.69 1.06 0.66 0.90 0.83 2.20 0.93 0.81 1.20 1.01 0.45
PLC
Control (10) 0.86 0.36 0.80 1.19 0.58 0.51 1.28 1.07 0.86 0.35 0.79 0.33 Min 0 0.69 0.45 0.65 1.05 0.59 0.61 0.88 0.62 1.00 0.84 0.74 0.19 Min 10 0.90 0.42 0.94 1.25 1.01 0.79 0.97 1.60 0.76 0.98 0.96 0.31 Min 20 0.96 0.16 0.68 1.28 0.95 0.77 1.09 1.37 1.35 0.84 0.95 0.37 Min 30 0.84 0.24 1.51 1.24 0.57 0.76 0.88 1.06 0.94 1.11 0.91 0.35
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (10) 1.40 0.67 0.52 0.62 0.65 0.57 0.78 0.56 0.69 0.70 0.26 Min 0 1.61 0.52 0.81 1.00 0.56 0.76 1.13 0.71 1.35 0.97 0.94 0.35 Min 10 3.19 0.85 1.76 1.10 1.02 0.98 0.70 1.29 0.99_ 2.02 1.39 0.75 Min 20 5.19 0.91 1.72 1.02 1.23 1.24 1.24 1.01 1.01 3.16 1.77 1.37 Min 30 3.08 1.27 1.61 0.85 1.24 1.01 2.24 1.26 1.09 3.45 1.71 0.91
PLC
Control (10) 0.57 0.67 0.61 0.58 0.99 1.21 0.94
_
1.11 0.66 1.19 0.85 0.26 Min 0 0.37 0.27 0.45 0.86 0.55 0.53 0.62 0.52 0.92 0.62 0.57 0.20 Min 10 2.31 0.40 1.26_ 0.80 1.13 1.42 1.11 0.61 1.49 1.16 1.17 0.53 Min 20 1.73 0.56 1.57 0.91 1.36 0.97 1.63 0.85 1.12 1.98 1.27 0.46 Min 30 1.57 0.77 1.51_ 0.75, 1.56_ 1.48 2.60 1.09 1.30 1.41 1.40_ 0.52TABLE 10. Plasma glycerol concentrations (mM).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD NAL
Control (-10) 0.60 0.77 1.00 0.67 0.25 1.20 0.99 0.33 0.47 1.20 0.75 0.34 Min 0 0.44 0.75 0.97 0.65 0.39 1.21 0.87 0.20 0.40 1.14 0.70 0.34 Min 10 0.67 0.84 1.21 0.63 0.59 1.66 0.90 0.33 0.98 1.51 0.93 0.42 Min 20 1.04 0.86 1.51 0.68 0.66 2.52 1.09 0.31 1.62 2.17 1.25 0.70 Min 30 1.32 0.91 1.73 0.76 0.99 2.98 1.36 0.45 1.82 2.96 1.53 0.87
PLC
Control (-10) 0.47 0.87 0.20 0.83 0.18 1.46 0.91 0.95 0.53 1.07 0.75 0.40 Min 0 0.59 0.98 -0.31 0.81 0.67 1.15 0.91 0.95, 0.54 1.08 0.74 0.42 Min 10 0.85 1.60 0.68 0.78 0.57 1.62 1.02 1.02 0.76 1.19 1.01 0.37 Min 20 1.10 1.00 1.24 0.81 0.58 2.42 1.19 1.00 0.66 1.34 1.13 0.51 Min 30 1.57 1.32 2.53 0.85 0.61 2.89 1.52 1.18 0.79 1.61 1.49 0.74
ALT #2 #5 #6 #7 #8 #11 ',#13 #14 #15 #17 Mean SD NAL
Control (-10) 1.07 0.19 0.68 0.76 0.75 0.34 1.20 0.91 0.98 0.04 0.69 0.39 Min 0 0.68 0.20 0.61 0.92 0.72 0.46 0.97 0.91 1.00 0.07 0.65 0.32 Min 10 2.71 0.32 1.18 1.30 0.82 0.55 1.01 1.02 1.13 0.10 1.01 0.71 Min 20 2.47 0.44 1.21 1.41 2.02 0.77 0.98 1.37 1.18 0.32 1.22 0.66 Min 30 2.47 0.76 1.46 1.25 2.49 1.01, 1.21 2.00 1.37 0.29 1.43 0.71
PLC
Control (-10) 0.80 0.23 0.16 0.95 0.69 0.49 1.15 0.88 0.98 0.11 0.64 0.37 Min 0 0.92 0.15 0.39 0.94 0.66 0.40 1.33 0.86 1.02 0.08 0.67 0.41 Min 10 1.06 0.23 0.32 1.18 0.78 0.56 1.20 0.93 1.09 0.50 0.79 0.36 Min 20 1.94 0.55 0.46 1.62 1.63 1.14 1.40 1.19 1.43 0.88 1.22 0.48 Min 30 2.94 0.39 0.62 1.68 1.73 0.95 1.50 1.36 1.63 1.42 1.42 0.70TABLE 11. Plasma free fatty acid concentrations (mM).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD NAL
Control (-10) 0.22 0.16 0.34 0.08 0.17 0.70 0.32 0.13 0.37
_
0.54 0.30 0.20 Min 0 0.27 0.19 0.33 0.07 0.17 0.61 0.24 0.11 0.36 0.55 0.29 0.18 Min 10 0.22 0.13 0.23 0.04 0.10 0.57 0.15 0.08 0.25 0.35 0.21 0.16 Min 20 0.25 0.15 0.34 0.09 0.13 0.86 0.28 0.13 0.39 0.45 0.31 0.23 Min 30 0.30 0.21 0.41 0.13 0.38 0.94 0.43 0.16 0.45 0.63 0.40 0.24
)
PLC
Control (-10) 0.26 0.23 0.25 0.05 0.22 0.84 0.43 0.10 0.28 0.28 0.30 0.22 Min 0 0.28 0.23 0.33 0.04 0.20 0.61 0.28 0.14 0.24 0.26 0.26 0.15 MM 10 0.33 0.30 0.30 0.01 0.10 0.67 0.32 0.08 0.16 0.15 0.24 0.19 Min 20 0.41 0.18 0.52 0.02 0.21 0.89 0.56 0.11 0.17 0.16 0.32 0.27 Min 30 0.43 0.31 0.62 0.03 0.39 1.12 0.74 0.17 0.22 0:24 0.43 0.32
1- ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD NAL
Control (-10) 0.78 0.32 0.46 0.15 0.82 0.22 0.20 0.50 0.18 0.38 0.40 0,24 Min 0 0.61 0.32 0.38 0.11 0.76 0.22 0.16 0.56 0.17 0.39 0.37 0.21 Min 10 0.42 0.13 0.20 0.07 0.41 0.10 0.09 0.18L 0.09 0.17 0.19 0.13 Min 20 0.58 0.14 0.25 0.07 0.49 0.11 0.07 0.26 0.10 0.16 0.22 0.18 Min 30 0.69 0.14 0.32 0.06 0.57 0.15 0.11 0.35 0.13 0.17 0.27 0.21
. - . .
PLC
Control (-10) 1.03 0.35 0.31 0.26 0.29 0.20 0.59 0.19 0.21 0.74 0.42 0.28
Min 0 0.73 0.35 0.37 0.25 0.25 0.19 0.53 0.20 0.19 0.71 0.38 0.21 Min 10 0.46 0.14 0.16 0.11 0.14 0.10. 0.24 0.06 0.08 0.36, 0.19 0.13 Min 20 0.65 0.17 0.19 0.16 0.13 0.15 0.33 0.12 0.11 0.34 0.24 0.17 Min 30 0.71 0.15 0.24 0.19 0.15 0.17 0.38 0.13 0.11 0.58 0.28 0.21TABLE 12. Respiratory exchange ratio.
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 0.85 0.86 0.76 0.87 0.86 1.00 0.84 0.88 0.75 0.77 0.84
.
0.07
Min 0 0.85 0.85 0.78 0.86 0.88 0.87 0.83 0.87 0.81 0.82 0.84 0.03
Min 10 0.89 0.90 0.84 0.94 0.89 0.85 0.90 0.90 0.79 0.81 0.87 0.05
Min 20 0.86 0.90 0.84 0.90 0.88 0.82 0.87 0.87 0.79 0.81 0.85 0.04 Min 30 0.86 0.87 0.82 0.91 0.88 0.80 0.85 0.87 0.78 0.80 0.85 0.04
PLC
Control (-10) 0.83 0.85 0.79 0.93 0.80 0.77 0.71 0.87 0.93 0.79 0.83 0.07 Min 0 0.85 0.85 0.81 0.85 0.82 0.81 0.70 0.85 0.81 0.84 0.82 0.05 Min 10 0.85 0.85 0.80 0.94 0.86 0.80 0.85 0.93 0.90 0.88 0.87 0.05 Min 20 0.83 0.86 0.79 0.92 0.82 0.78 0.81 0.93 0.87 0.84 0.85 0.05 Min 30 0.82 0.86 0.79 0.93 0.83 0.79 0.83 0.92 0.85 0.84 0.84 0.05
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD NAL
1
Control (-10) 0.72 0.86 0.79 0.90 0.75 1.10 0.92 0.62 0.84 0.79 0.83 0.13 Min 0 0.72 0.94 0.71 0.91 0.77 0.88 0.92 0.77 0.86 0.80 0.83 0.09 Min 10 0.86 0.89 0.89 0.95 0.88 0.93 0.95 0.87 0.86 0.93 0.90 0.04
Min 20 0.84 0.89 0.88 0.94 0.86. 0.90 0.97 0.86 0.84 0.92, 0.89 0.04 Min 30 0.81 0.87 0.87 0.98 0.86 0.91 1.05 0.86 0.85 0.91 0.90 0.07
PLC
Control (-10) 0.84 0.90 0.79 0.87 0.82 0.75 0.81 0.80 0.83 0.69 0.81 0.06
Min 0 0.71 0.92 0.77 0.84 0.80 0.76 0.80 0.83 0.79 0.72 0.80 0.06
Min 10 0.82 0.91 0.94 0.84 0.88 0.88 0.88 0.84 0.87 0.91 0.88 0.04
Min 20 0.80 0.89 0.95 0.84 0.89 0.88 0.86 0.90 0.88 0.90 0.88 0.04 Min 30 0.83 0.90 0.93 0.82 0.89 0.85 0.89 0.85 0.86 0.89 0.87 0.03TABLE 13. Fatty acid oxidation (urnol/kg/min).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10) 2.2 2.2 6.1 2.8 2.1 -0.9 2.7 2.3 4.1 4.5 2.8 1.8
Min 0 2.6 2.6 4.3 2.6 1.8 2.3 2.4 2.0 3.0 3.6 2.7 0.8
Min 10 22.3 12.6 36.7 11.8 20.6 25.7 15.8 16.5 37.6 41.7 24.1 11.0
Min 20 28.9 13.6 39.9 20.8 24.0 32.0 21.3 21.9 36.9 43.0 28.2 9.5
Min 30 29.6 16.9 42.8 18.5 23.0 35.2 23.1 23.9 40.4 45.6 29.9 10.4
PLC
Control (-10) 1.8 2.4 3.8 1.2 5.2 4.7 5.9 3.1 0.6 4.0 3.3 1.8
Min 0 1.0 3.5 4.2 4.1 3.7 3.6 8.5 3.4 3.1 3.5 3.8 1.9
Min 10 30.5 17.6 47.8 14.6 27.7 37.6 23.1 11.2 17.7 22.4 25.0 11.2
Min 20 34.9 16.4 49.7 17.9 36.7 42.5 31.4 12.5 21.8 33.1 29.7 12.1
Min 30 36.2 16.9 51.6 15.6 36.5 41.3 29.4 14.5 25.4 32.2 30.0 12.1
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10) 5.8 2.0 5.0 1.4 4.8 -3.5 1.3 9.1 2.7 4.8 3.3 3.4
Min 0 6.4 0.6 5.3 1.2 4.6 1.7 0.9 5.2 3.4 4.0 3.3 2.1
Min 10 33.2 29.7 27.9 11.1 30.2 13.3 12.2 29.7 40.8 12.0 24.0 10.8
Min 20 38,3 31.0 30.4 12.1 35.4 20.9 6.1 31.3_ 46.3 15.0_ 26.7 12.7
Min 30 45.5 36.6 34.2 3.5 35.3 18.2 -15.3 33.9 43.8 19.1 25.5 19.3
PLC
Control (-10) 3.0 1.8 4.6 0.7 4.0 7.5 4.1_ 4.2 3.8 8.6 4.2 2.4
Min 0 7.2 0.9 6.3 1.1 4.5 6.1 4.3 3.2 6.4 7.5 4.7 2.4
Min 10 41.2 22.0 16.0 37.9 31.1 24.9 30.2 37.9 35.6 18.0 29.5 8.9
Min 20 49.0 28.7 13.0 40.3 29.3 25.6 37.3 23.7 34.1 22.4 30.3 10.3
Min 30 45.4 25.4 18.5 44.0 29.3 32.0 30.1 33.7 39.2 23.3 8.8
OTABLE 14. Carbohydrate oxidation (umol/kg/min).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
'Control (-10) 11.7 12.1 4.5 17.4 13.1 26.5 11.3 19.0 1.6 4.5 12.2 7.5
Min 0 11.7 12.0 5.8 15.9 15.1 15.1 8.0 13.0 8.1 11.2 11.6 3.4
Min 10 163.8 118.0 143.8 218.7 167.3 110.8 132.0 141.8 68.5 100.7 136.5 41.5
Min 20 142.8 118.7 140.4 185.6 148.2 86.8 114.2 129.3 70.3 96.2 123.2 33.7
Min 30 140.8 102.4 122.8 198.7 156.8 74.2 106.0 126.0 61.0 89.7 117.8 40.8
PLC
Control (-10) 6.6 11.3 6.8 26.1 11.0 4.6 -2.0 19.2 19.7 6.8 11.0 8.4
Min 0 5.9 17.4 9.4 18.4 10.6 7.9 -3.2 15.2 6.9 13.5 10.2 6.4,
Min 10 129.4 75.5 102.0 252.4 134.2 78.6 103.4 159.5 147.6 146.8 132.9 51.1
Min 20 117.9 80.6 86.7 225.0 109.7 63.7 78.7 174.4 124.7 115.4 117.7 49.0
Min 30 104.2 80.0 83.5 235.6 110.5 67.4 92.4 171.9 110.6 119.0 117.5 50.4
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 Mean SD
NAL
_#17
Control (-10) -0.9 12.3 7.5 17.4 2.5 41.2 22.8 -12.0 11.2 8.3 11.0 14.4
Min 0 -0.8 25.0 -1.5 19.5 4.5 14.9 20.8 5.7 18.4 7.4 11.4 9.5
Min 10 166.8 211.2 208.3 237.6 198.6 197.7 257.2 172.8 187.2 195.6 203.3 27.5
Min 20 135.4 216.7 206.3 231.6 179.0 185.4 292.1 154.7 169.3 200.9 197.1 44.1
Min 30 106.0 196.1 182.8 282.8 172.5 191.7 433.6 159.3 179.0 195.4 209.9 89.8
PLC
Control (-10) 11.5 19.4 7.9 7.1 11.6 3.6 10.5 8.7 13.0 -3.8 8.9 6.1
Min 0 -0.9 17.8 7.0 5.3 9.4 5.6 8.2 11.1 11.7 -0.6 7.5 5.6
Min 10 118.6 240.6 273.6 136.3 204.1 161.8 200.3 140.5 201.5 187.6 186.5 48.4
Min 20 104.5 224.0 277.4 143.6 207.1 157.1 181.8 200.1 211.5 186.1 189.3 47.4
Min 30 149.2 232.3 266.0 119.8 206.1 136.4 226.1 151.6 196.2 182.5 186.6 47.2TABLE 15. Total energy expenditurecal/kg/min).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10 14.1 14.5 19.0 19.8 14.9 16.7 15.2 19.6 11.7 14.9 16.0 2.7
Min 0 15.1 15.3 15.3 18.2 15.4 16.8 11.9 14.4 13.7 17.5 15.4 1.8
Min 10 175.7 117.5 198.3 187.9 173.8 146.2 135.9 144.6 146.4 180.2 160.6 26.0
Min 20 177.5 120.7 204.2 187.2 16811 145.2 137.1 149.7 145.9 180.3 161.7 25.9,
Min 30 177.8 117.5 198.9, 190.7 172.2 144.4 136.1 152.4 148.2 182.3 162.1 26.2
PLC
Control (-10 9.4 14.4 14.9 21.9 21.4, 15.4 13.9 21.8 15.7 15.3 16.4 4.1
Min 0 6.8 21.5 17.6 23.8
_..
17.2 14.9 19.6 19.8 12.9 18.6 17,3 4.8
Min 10 172.1 99.7 197.0 219.5 168.2 153.6 134.2 143.7 152.0 163.5 160.4 33.0
Min 20 175.0 100.5 190.8 208.3 173.7 155.5 137.8 157.8 146.2 168.5 1.1.4 29.8
Min 30 168.6 101.4 193.5 210.0 173.8 155.2 142.4 161.3 145.4 168.8 162.0 29.6
ALT #2 #5 #6 #7 #8
---)
411 #13 #14 #15 #17 Mean SD
NAL
Control (-10 14.2 13.9 18.4 16.2 14.1 20.6 19.7 14.9 15.0 18.3 16.6 2.5
Min 0 16.0 19.5 12.5 17.1 15.1 15.1 17.4 17.6 22.0 15.7 16.8 2.6
Min 10 205.8 228.7 221.9 199.7 221.1 176.8 216.8 201.1 240.2 171.9 208.4 21.9
Min 20 196.3 236.1 227.1 198.0 220.3 187.6 226.0 192.3 241.6 183.4 210.9 21.6
Min 30 193.9 235.8 220.1 212.6 215.4 185.0 272.8 202.2 242.1 189.9 217.0 27.2
PLC
Control (-10 16.0 18.5 17.5, 7.0 18.6 22.0_ 18.1 17.0 19.2 19.5 17.3 4.0
Min 0 17.9 15.2 21.2 6.6 18.3 19.7 17.0 16.2 25.1 18.8 17.6 4.8
Min 10 191.8 230.0 238.3 196.0 227.3 180.8 222.2 199.0 237.0 181.7 210.4 22.8
Min 20 201.9 235.5 233.2 207.5 224.8 179.2 227.3 205.3 240.4 191.7 214.7 20.5
Min 30 224.8 232.8 239.2
T
199.9 224.0 180.8 240.5 196.3 242.6 191.7 217.3 22.9TABLE 16. Energy expenditure from carbohydrate (cal/kg/min).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10 8.4 8.7 3.2 12.5 9.4 19.1 8.2 13.7 1.2 3.3 8.8 5.4
Min 0 8.5 8.7 4.2 11.5 10.9 10.9 5.7 9.4 5.8 8.0 8.3 2.5
Min 10 117.9 85.0 103.6 157.5 120.4 79.8 95.0 102.1 49.3 72.5 98.3 29.8
Min 20 102.8 85.4 101.1 133.6 106.7, 62.5_ 82.2 93.1_ 50.6 69.3 88.7 24.2
Min 30 101.4 73.8 88.4 143.0 112.9 53.4 76.3 90.7 43.9 64.5 84.8 29.4
PLC
Control (-10 4.8 8.1 4.9 18.8 7.9 '3.3 -1.4 13.9 14.2 4.9 7.9 6.0
Min 0 4.2 12.5 6.8 13.2 7.6 5.7, -2.3 11.0 5.0 9.7 7.3 4.6
Min 10 93.2 54.3 73.4 181.7 96.6 56.6 74.5 114.8 106.3 105.7 95.7 36.8
Min 20 84.9 58.0 62.4 162.0, 79.0 45.9 56.7 125.5 89.8 83.1 84.7 35.3,
Min 30 75.0 57.6 60.1 169.7 79.6 48.5 66.6 123.8 79.6 85.7 84.6 36.3
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10 -0.6 8.9 5.4 12.5 1.8, 29.6 16.4 -8.6 8.1 6.0 7.9 10.3
Min 0 -0.6 18.0 -1.1 14.0 3.2 10.7 15.0 4.1 13.3 5.3 8.2 6.8
Min 10 120.1 152.1 149.9 171.1 143.0 142.3 185.2 124.4 134.8 140.8 146.4 19.8
Min 20 97.5 156.1 148.6 166.7, 128.9_ 133.5 210.3 111.4 121.9 144.6 141.9 31.8
Min 30 76.3 141.2 131.6 203.6 124.2 138.0 312.2 114.7 128.9 140.7 151.1 64.7
PLC
Control (-10 8.3 14.0 5.7 5.1 8.3 2.6 7.5 6.3, 9.3 -2.7 6.4 4.4
Min 0 -0.7, 12.8 5.1 3.8 6.8 4.1 5.9 8.0 8.4 -0.4 5.4 4.1,
Min 10 85.4 173.3 197.0 98.1 147.0 116.5 144.2 101.1 145.1 135.1 134.3 34.9
Min 20 75.3 161.3 199.7 103.4 149.1 113.1 130.9 144.1 152.3 134.0 136.3 34.2
Min 30 107.4 167.3 191.5 86.3 148.4 98.2 162.8 109.2 141.3 131.4 134.4 34.0TABLE 17. Energy expenditure from fat (cal/kg/min).
BLT #1 #3 #4 #9 #10 #12 #16 #18 #19 #20 Mean SD
NAL
Control (-10 5.7 5.8 15.7 7.3 5.5 -2.3 7.0 6.0 10.6 11.6 7.3 4.7
Min 0 6.7 6.6 11.2 6.7 4.5 5.9 6.1 5.0 7.9 9.4 7.0 2.0
Min 10 57.7 32.5 94.8 30.5 53.3 66.4 40,8 42.5 97.1 107.7 62.3 28.3
Min 20 74.7 35.2 103.1 53.6 62.1 82.7 54.9 56.5 95.3 111.0 72.9 24.6
Min 30 76.4 43.7 110.5 47.7 59.3 91.0 59.8 61.7 104.3 117.8 77.2 27.0
PLC
Control (-10 4.6 6.3 9.9 3.1 13.5 12.1 15.3
.-
8.0 1.5 10.4 8.5 4.6
MM 0 2.5 9.0 10.8 10.6 9.6 9.3 22.0 8.8 7.9 8.9 9.9 4.8
Min 10 78.9 45.4 123.6 37.8 71.6 97.1 59.8 28.9 45.7 57.8 64.6 29.0
Min 20 90.1 42.4 128.4 46.3 94.7 109.7 81.1 32.3 56.4 85.4 76.7 31.3
Min 30 93.6 43.8 133.4 40.3 94.2 106.7 75.8 37.6 65.7 83.1 77.4 31.3
ALT #2 #5 #6 #7 #8 #11 #13 #14 #15 #17 Mean SD
NAL
Control (-10 14.9 5.1 13.0 3.7 12.3 -9.1 3.3 23,5 7.0 12.4 8.6 8.7
Min 0 16.6 1.5 13.6 3.0 11.8 4.4 2.4 13.5 8.7 10.4 8.6 5.4
Min 10 85.7 76.6 72.0 28.6 78.1 34.5 31.6 76,7 105.4 31.0 62.0 27.9
Min 20 98.9 80.1 78.5 31.2 91.4 54.1 15.7 80.8 119.7 38.8 68.9 32.9
Min 30 117.6 94.6 88.5 9.0 91.2 47.0 -39.4 87.5 113.2 49.2 65.8 49.8
PLC
Control (-10 7.7 4.6 11.9 1.9 10.3 19.3 10.5 10.8 9.9 22.3 10.9 6.1
Min 0 18.6 2.4 16.2 2.8 11.5 15.7 11.1 8.2 16.7 19.3 12.2 6.2
Min 10 106.4 56.8 41.3 97.9 80.3 64.3 78.0 97.8 91.9 46.6 '16.1 22.9
Min 20 126.7 74.2 . 33.5 104.1 75.7 66.1 96.4 61.3 88.1 57.8 78.4 26.5
Min 30 117.4 65.5 47.7 113.7 75.6 82.7 77.7_ 87.1 101.3 60.3 82.9 22.7I
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